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POST-TRANSCRIPTION REGULATION OF THE TYPE IIA SODIUM-PHOSPHATE 
COTRANSPORTER BY PARATHYROID HORMONE 
 
Rebecca D. Murray 
November 24, 2014 
 
 
 The type IIa sodium-phosphate cotransporter (Npt2a) is expressed in the apical 
membrane of the renal proximal tubule and is responsible for the reabsorption of the 
majority of the filtered load of phosphate. Parathyroid hormone (PTH) is secreted by the 
parathyroid gland in response to a decrease in serum calcium or an increase in serum 
phosphorus, and acutely induces phosphaturia through the rapid stimulation of 
endocytosis of Npt2a and its subsequent lysosomal degradation. Chronic PTH stimulation 
leads to sustained phosphaturia, but the mechanisms for the chronic regulation of Npt2a 
by PTH remain unclear. We hypothesize that PTH decreases Npt2a mRNA levels as a 
mechanism for inducing chronic phosphaturia. We address this hypothesis within three 
specific aims. The first specific aim addresses the kinetics and mechanisms of the PTH-
stimulated decrease in Npt2a mRNA expression. The second aim details the signaling 
pathways involved in PTH-mediated downregulation of Npt2a mRNA. Lastly, the third 
aim characterizes the PTH-responsive phosphoproteome of the proximal tubule, and how 
changes in the expression and phosphorylation of RNA-binding proteins may affect 
Npt2a mRNA stability. 
vi 
 
In Aim 1, we found that PTH decreases Npt2a steady-state mRNA levels with a 
50% loss in 2.2h compared to 8.6h in the absence of PTH. This effect is post-
transcriptional, and is dependent on both transcription and translation. In Aim 2, we 
determined that PTH destabilizes Npt2a mRNA through both PKA- and PKC-dependent 
mechanisms. The rapid initial decline in Npt2a mRNA levels corresponds to and appears 
to be dependent on early PTH-stimulated PKA activation. In contrast, PTH-stimulated 
PKC activation occurs more gradually over several hours and likely contributes to the 
latter phase of Npt2a mRNA destabilization. Finally, in Aim 3, we found that PTH alters 
the phosphorylation status of almost 1200 proteins in the proximal tubule, including 68 
RNA-binding proteins (RBPs). Two of those RBPs, KHSRP and Roquin-2, bind to Npt2a 
mRNA, and their expression varies inversely with Npt2a mRNA levels. From these 
studies, we conclude that PTH-mediated Npt2a mRNA destabilization likely occurs 
through PKA- and PKC-dependent modulation of RBP expression and activity, and that 
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“Where there’s life there’s phosphorus” 
 
Since the initial isolation of adenosine triphosphate from muscle extracts in 1929, 
phosphate has been at the heart of physiology. The aforementioned quote is known as 
Todd’s Hypothesis, after the biochemist Alexander Todd (1907-1997) who was the first 
to chemically synthesize the ATP molecule in 1948, for which he later won the Nobel 
Prize in 1958
1
. The phosphate ester bond is a uniquely flexible chemical bond, with the 
ability to form extremely stable bonds capable of enduring millions of year (DNA) as 
well as extremely transient bonds that last mere milliseconds. In the years following the 
discovery of ATP, scientists have uncovered numerous biological processes in which 
phosphate is a critical element. At the underpinning of life as we know it, phosphate is 
essential in formation of deoxy- and ribonucleic acids
2
. Apart from being an integral part 
of the genetic code, the second major function of phosphate within the body is to provide 
whole organism structure through the development and maintenance of the skeleton. In 
the form of ATP, phosphate is also an essential component of the ubiquitous energy 
currency for cellular metabolism
3–5
. Intracellular signaling and secondary messenger 
cascades are heavily reliant on the use of phosphate as an on- or off-switch in the 





Within the body, phosphate is a ubiquitous mineral, and is present as inorganic 
phosphate, the vast majority of which is located within bone and teeth (85%), with the 
bulk of the remainder being found in soft tissues (14.3%); interstitial fluid, plasma, and 
red blood cells each account for less than three-tenths of a percent of the total body 
phosphate content
7
. In addition to the major physiological functions previously 
mentioned, phosphate also plays several other roles within the body. Divalent phosphate 
(HPO4
2-
) is an important physicochemical buffer, maintaining pH balance during states of 
acidosis. It provides structure not only at the macromolecular level in the form of bone 
mineralization and formation, but also at the cellular level, providing organization and 
compartmentalization through the stability and amphipathic nature of phospholipids. 
Phosphate also aids in oxygen transport through the interaction of 2,3-diphosphoglycerate 
with hemoglobin
7
. As a crucial biological mineral, phosphate and the processes 
underlying its homeostasis remain significant areas of research. 
 
Pathophysiology of phosphorus 
The fact that total body phosphate homeostasis is crucial for cardiovascular health 
is one of the most significant findings of the last two decades
8–10
. Dysregulation of 
phosphate homeostasis, including both hyperphosphatemia and hypophosphatemia, can 
result in severe pathophysiological conditions. Normal clinical values for serum 
phosphorus have been defined as 3.4 to 4.5 mg/dL
11
. Even mild hyperphosphatemia with 
serum values of 5.5 mg/dL or greater correlate with a statistically significant increase in 
the risk of death from cardiovascular and renal diseases
12
. Increased serum phosphorus 
accompanying chronic kidney disease is associated with such cardiovascular 
complications as vascular calcification and toxicity
13,14
. In addition to elevated serum 
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phosphorus leading to increased precipitation of calcium-phosphate deposits within the 
body, research indicates that the presence of excess phosphate itself can be detrimental to 
cell function, particularly in cardiovascular cells. Vascular smooth muscle cells cultured 
in a high phosphorus medium displayed upregulated expression of bone-promoting 
differentiation markers that facilitate extracellular matrix calcification
15,16
. Phosphate has 
been implicated as a pro-aging factor
6
, producing not only vascular pathologies such as 
ectopic calcification and arteriosclerosis, but also contributing to the development of 
COPD, chronic kidney disease, and hearing loss. Aside from cardiovascular 
complications, it is thought that diets chronically high in phosphorus strongly contribute 
to bone disorders in aging
17
. Accumulation of phosphate has even been implicated in the 
development of muscle fatigue during prolonged exercise
18
. 
Just as high serum phosphorus produces increased cardiovascular morbidity and 
mortality, too little phosphorus can produce pathologies just as detrimental. 
Hypophosphatemia can have severe cardiovascular repercussions including vasodilation, 
hemolysis, and cardiac failure
19
. Additionally, many bone diseases are attributed to 
hypophosphatemia. Perhaps most notably, the hereditary skeletal disorder autosomal 
dominant hypophosphatemic rickets results from renal phosphate wasting, producing 
severe bone malformation
20
. Other bone diseases also resulting from hypophosphatemia 
include X-linked hypophosphatemia as well as hereditary hypophosphatemic rickets with 
hypercalciuria. Phosphate is a crucial component of the bone mineral hydroxyapatite, and 
hypophosphatemia not only causes decreased bone mineralization and fragility but also 
pain and growth retardation
21
. With so many roles in the body and so many potential 
pathologies from the dysregulation of phosphate, its maintenance and regulation thus 
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represent a crucial component of cardiovascular and bone health, with serious 
implications for clinical morbidity and mortality. 
 
Determinants of serum phosphorus 
Total body phosphate homeostasis is tightly maintained through a complex axis 
involving the intestines, kidneys, and bones. While the minimum daily dietary 
requirements for phosphorus are approximately 20 mmol/day
7
, the Western diet typically 
contains a much higher amount than stipulated by metabolic needs. In adults, serum 
phosphorus levels result from a combination of dietary intake, bone modeling, and kidney 
excretion rates, the last of which is the most crucial determinant of serum phosphorus. 
Dietary phosphate can be obtained from all natural foods, with particular abundance in 
protein-rich food as well as cereal grains
2
. Phosphorus obtained from animal sources is 
more bioavailable and more readily absorbed than phosphate obtained from plant 
sources
22
. In more recent years, dietary loads of phosphate have increased through the 
heavy reliance of the food industry on phosphate-rich food additives to preserve food 
shelf life
22
. In the steady state, however, the amount of phosphate absorbed from the diet 
is balanced by the amount of phosphate excreted by the kidney. 
In the gut, absorption of dietary phosphate into the circulation occurs through 
paracellular pathways and through transcellular pathways mediated primarily by the type 
IIb sodium-phosphate cotransporter (Npt2b), expressed in the apical membrane of the 
duodenum and early jejunum
17
. While Npt2b expression is known to be regulated by 
intestinal phosphate content, the specific mechanisms governing regulation of intestinal 
phosphate transport remains poorly understood. In addition to the contribution of the gut 
to phosphate homeostasis, bone also plays a major role in phosphate homeostasis, as the 
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hydroxyapatite matrix serves as a critical pool of phosphorus and calcium reserves. Adult 
bones undergo constitutive remodeling, with phosphate and calcium cycling into and out 
of the bones and circulation as osteoclastic bone resorption is countered by osteoblastic 
bone formation
23
. The flux of phosphate into and out of bone is normally balanced in the 
adult, and thus serum phosphorus levels are mostly determined by the rate of renal 
excretion.  
In the kidney, approximately one-fifth of renal plasma flow is filtered into 
Bowman’s space. This renal ultrafiltrate then enters the nephron, wherein water and 
solutes will either be reclaimed back into the circulation, or pass through to be excreted in 
the final urine. A small solute, phosphate is freely filtered at the glomerulus, and its 
reabsorption within the nephron occurs almost exclusively in the proximal tubule
24
. 
Phosphate does not undergo secretion within any segment of the nephron, and thus rates 
of renal phosphate excretion are dependent on the rate of phosphate reabsorption from the 
ultrafiltrate of the glomerulus. The proximal tubular transport maximum for phosphate 
reabsorption is directly related to the abundance of phosphate transporters expressed 
within the apical membrane. Once the transport maximum is reached, any excess filtered 
phosphate will end up in the final urine. Phosphate is reclaimed from the ultrafiltrate 
through secondary-active transport coupled to the movement of sodium down its 
concentration gradient, which allows for entry of phosphate from the tubule lumen into 
the tubular epithelial cell.  Reabsorption of phosphate back into the bloodstream is 





Contribution of phosphate transporters to renal phosphate reabsorption 
Mammalian phosphate transport is accomplished by two families of secondary-
active sodium-coupled phosphate transporters: SLC20 and SLC34. The SLC20 family is 
comprised of PiT-1 (SLC20A1) and PiT-2 (SLC20A2). PiT-1 and PiT-2 mRNAs are 
ubiquitously expressed in both murine and human tissue, and they are thought to serve a 
housekeeping function of providing phosphate for intracellular metabolic needs
25,26
. 
Within the kidney, although expression of both PiT-1 and PiT-2 has been found, only 
PiT-2 has been identified in the apical membrane of the proximal tubule
27
. 
The SLC34 family is comprised of Npt2a (SLC34A1) and Npt2c (SLC34A3). 
Both Npt2a and Npt2c are expressed in the apical membrane of the proximal tubule, with 
Npt2a expression seen throughout the proximal tubule, while Npt2c expression exhibits 
heavier expression in the early segments of juxtaglomerular proximal tubules. Npt2a is an 
electrogenic transporter, cotransporting three sodium ions and one divalent phosphate ion 




), whereas Npt2c is electroneutral, coupling the entry of two 




). Both Npt2a and Npt2c are 
the primary mediators of proximal tubule reclamation of filtered phosphate with PiT-2 
contributing only a small fraction to overall phosphate reabsorption
20,28,29
. 
In rodents, the type IIa sodium-phosphate cotransporter (Npt2a) has been 
identified as the transporter responsible for the majority of phosphate reabsorption, 
accounting for up to 80% of brush-border phosphate transport
30–32
. Studies in mice 
support a preeminent role for Npt2a in contributing to overall phosphate homeostasis, as 
Npt2a knockout mice not only display significant phosphate wasting, but they also 
develop hypercalciuria with tubular and interstitial calcium-phosphate deposits, and 
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display developmental skeletal abnormalities
33–35
. Ablation of the Npt2c gene in mice 
does not elicit a hypophosphatemic phenotype, with no apparent disturbances in calcium 
or phosphate homeostasis
36
.  Studies of protein dynamics in the proximal tubule show 
that in response to PTH, Npt2a is endocytosed and sent to the lysosomes for degradation, 
whereas Npt2c is endocytosed but escapes lysosomal degradation, which suggests that 
control of Npt2a expression may be more important for rapid and sustained changes in 
proximal tubule phosphate reabsorption
37
. 
The contribution of the renal phosphate transporters to overall phosphate 
homeostasis may be species-specific, however. Clinical syndromes associated with Npt2a 
and Npt2c gene mutations suggest that Npt2c expression and function may be more 
important for total phosphate homeostasis than Npt2a in humans. Loss-of-function 
mutations in the human Npt2c gene have been identified as the cause of hereditary 
hypophosphatemic rickets with hypercalciuria and accompanying nephrolithiasis renal 
phosphate wasting
6,38
. In contrast, human Npt2a mutations were found to be associated 
with a considerably milder phenotype of osteoporosis and nephrolithiasis
39,40
. However, 
recent clinical reports suggest a more significant role for Npt2a expression and function 
in human phosphate homeostasis than previously thought. Magen et al.
41
 reported a 
clinical case of autosomal recessive hypophosphatemic rickets with renal Fanconi’s 
Syndrome secondary to an Npt2a loss-of-function genetic mutation. Likewise, Rajagopal 
et al.
42
 and Kenny et al.
43
 both reported case studies of mutations in the Npt2a gene that 
resulted in phenotypes of renal phosphate wasting with resultant hypercalcemia, 
hypercalciuria, and hypophosphatemia. While these clinical reports suggest that the 
contribution of specific renal phosphate transporters to overall phosphate homeostasis 
8 
 
may be more nuanced than previously recognized, they provide evidence and support for 
Npt2a as an important determinant of serum phosphorus, as well as a critical target of 
regulators of renal phosphate reabsorption. 
 
Regulation of serum phosphorus 
The maintenance of serum phosphate is dependent on the rate of its reabsorption 
in the kidney, which is subject to strict regulation by a host of factors, including diet and 
hormones. Npt2a expression and function are determined by physiologic regulators of 
serum phosphorus, including parathyroid hormone (PTH), one of the major phosphaturic 
hormones
34
. The amount of phosphate in the diet regulates phosphate reabsorption in the 
kidney, independent of changes in serum phosphorus, as low-phosphate diets upregulate 
proximal tubular phosphate reabsorption prior to any changes in serum phosphorus
44
. 
Apart from dietary regulation, phosphate reabsorption is also modulated by a host of 
hormonal factors. Several factors that increase renal phosphate reabsorption include 
growth hormone, insulin-like growth factor 1, insulin, thyroid hormone, and 
stanniocalcin. These factors, however, play a minor role in phosphate homeostasis as 
compared to the major hormonal regulators of renal phosphate reabsorption – PTH, 
fibroblast growth factor 23 (FGF23), and vitamin D
6,45
. 
PTH is an 84-amino acid peptide hormone that is released from the parathyroid 
glands in response to either decreased serum Ca
2+
 or increased serum Pi
46
. In bone, PTH 
stimulates osteoclastic activity indirectly through its effect on osteoblast secretion of 
paracrine factors
2,47
. As shown in Figure 1, bone resorption as a result of PTH stimulation 
releases Ca
2+
 and Pi into the circulation. In the proximal tubule, PTH upregulates 1α-
9 
 
hydroxylase expression, which enhances production of 1,25-dihydroxy-vitamin D, 
promoting increased calcium absorption in the gut
48
. In the process of releasing calcium 
from bone, phosphate stores also become liberated. To excrete the excess phosphate and 
preserve the newly restored serum calcium level, PTH exerts a phosphaturic effect in the  
FIGURE 1 
 
Figure 1: Regulation of serum Ca
2+
 and Pi by PTH. Low serum Ca
2+
 stimulates the 





 into the bloodstream. At the kidney, PTH increases 
Ca
2+
 reabsorption and decreases HPO4
2-
 reabsorption, maintaining the elevated serum 
Ca
2+
 from the resorption of bone. Vitamin D becomes activated in the kidney by 1α-
hydroxylase, leading to increased Ca
2+
 absorption from the gut. The restored serum Ca
2+
 




kidney to decrease the reabsorption of phosphate from the plasma ultrafiltrate, while 
simultaneously increasing calcium reabsorption in the distal tubule to sustain the 
elevation in serum calcium
7,49
. As serum PTH levels increase, the renal transport 
maximum for phosphate decreases
50
, which is accomplished through the downregulation 
of both of the major renal phosphate transporters, Npt2a and Npt2c
51
.  
 FGF23 is secreted from the bone and is another potent phosphaturic hormone that 
in conjunction with Klotho decreases the renal transport maximum for phosphate by 
decreasing the abundance of Npt2a and Npt2c, as well as PiT-2, in the BBM of the 
proximal tubule
52
. Klotho is the co-receptor for FGF23, and also circulates as an 
endocrine factor to promote anti-aging systemic effects
54
. FGF23 exerts its 
hypophosphatemic effects independent of and synergistically with PTH
53
, and plays a 
prominent role throughout the development of chronic kidney disease (CKD), as FGF23 
expression increases exponentially with the progressive decline of kidney function and 
resultant increase in serum phosphate
54
. Consistent with these effects, FGF23-
overexpressing mice display hypophosphatemia with decreased transcript and protein 
expression of Npt2a
55
. Conversely, mice with FGF23 gene ablation display increased 
serum phosphate, increased apical expression of Npt2a, and an accompanying increase in 
the renal phosphate transport maximum
53
. Distal-tubule-specific deletion of Klotho also 
produces a phenotype of hyperphosphatemia with abundant Npt2a BBM expression
56
. 
However, the actions of FGF23 on Npt2a expression are distinct from the actions of PTH, 
as PTH-induced phosphaturia is elicited through PKA- and PKC-dependent pathways, 





Additionally, PTH appears to be a calcium-centric hormone, with secondary effects on 
phosphate homeostasis, whereas FGF23 is more phosphate-centric. 
 While the actions of PTH and FGF23 on proximal tubular phosphate reabsorption 
are direct and relatively straight-forward, the actions of vitamin D on phosphate 
reabsorption, and Npt2a in particular, are complex. Acutely, vitamin D appears to 
stimulate phosphate reabsorption by increasing expression of Npt2a through upregulation 
of Npt2a promoter activity in a cell-specific manner, although this action appears to have 
a weak direct influence on phosphate transport
59
. Rather, vitamin D appears to play a 
more important role in overall phosphate homeostasis by modulating the 
FGF23/Klotho/PTH bone-endocrine axis
6
. PTH stimulates the formation of active 
vitamin D, which, in a negative feedback loop, suppresses further PTH release from the 
parathyroid glands
60,61
. Vitamin D also increases FGF23 expression, which decreases 
renal 1α-hydroxylase expression in addition to promoting phosphaturia
62
. Despite vitamin 
D’s direct and indirect actions in the proximal tubule to increase apical membrane 
phosphate transport, chronic exposure to vitamin D has actually been shown to decrease 
Npt2a expression synergistically with PTH, likely in response to increased phosphate 
release from increased bone turnover
63
. 
PTH and FGF23 are the most prominent regulators of serum phosphorus, 
although other important physiological factors have also been shown to play a more 
minor role in phosphate homeostasis. Secreted frizzled-related protein 4 (Sfrp4) has been 
implicated as an acute downregulator of Npt2a expression in the proximal tubule, but 
genetic ablation studies were unable to show a chronic physiologically-relevant role of 
this protein in overall phosphate homeostasis
64
. Estrogen has phosphaturic actions that 
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induces phosphate wasting through the downregulation of Npt2a mRNA and protein 
expression, but produces no effect on the expression of either Npt2c or PiT-2
5
. Other 
regulators of serum phosphate with less dramatic effects on renal phosphate transport 
include dopamine, PTH-related-peptide, calcitonin, atrial natriuretic peptide, epidermal 
growth factor, and glucocorticoids
53,65
. While these and other factors regulate renal 
phosphate transport, PTH remains a critical determinant of phosphate reabsorption within 
the proximal tubule, and serves as an important hormonal regulator of proximal tubule 
function. 
 
Effects of PTH on proximal tubule ion transport and metabolism 
The effects of PTH on the proximal tubule are not limited to phosphate transport 
alone. As shown in Figure 2, PTH regulates several ion transporters and metabolic 
pathways. PTH stimulates gluconeogenesis through the actions of adenylyl cyclase
66,67
, 
as well as ammoniagenesis through the increased catabolism of glutamate
68
. In the 
kidney, reabsorption of filtered bicarbonate is dependent on sodium-hydrogen exchange 
across the apical membrane of the proximal tubule, a process that is also decreased by 
PTH through the decreased expression and activity of the sodium/hydrogen exchanger 
isoform 3 (NHE3)
69,70





), PTH decreases the transcellular transport of sodium within the 






Due to its systemic effects on the kidney, bone, and gut, PTH plays a crucial role 
in the maintenance of total body calcium and phosphate homeostasis. Imbalances in 







Figure 2: Effects of acute PTH on the proximal tubule. Acute stimulation of the 
proximal tubule by PTH results in (A) decreased hydrogen secretion through down-
regulation of NHE3, (B) decreased phosphate reabsorption through down-regulation 
of NpT2a, (C) increased gluconeogenesis, (D) increased ammoniagenesis, and (E) 








chronic elevated serum PTH causes increased serum calcium and decreased serum 
phosphorus levels. Accordingly, patients with untreated primary hyperparathyroidism 
display higher incidences of mineral disorders, including aortic valve calcification, 
hypertension, and kidney stones
72,73
. Acute stimulation of the proximal tubule by PTH 
results in downregulation of bicarbonate, sodium, and phosphate reabsorption, but 
clinical observations suggest that the chronic effects of PTH differ from the acute effects. 
Patients with primary hyperparathyroidism do not consistently display volume depletion 
or metabolic acidosis
74,75





. Whereas many PTH responses in the proximal tubule seemingly 
desensitize over time, downregulation of phosphate reabsorption persists. The studies 
presented within this dissertation seek to clarify the mechanism for the chronic 






Npt2a expression in the proximal tubule 
 
The rate of phosphate reabsorption in the proximal tubule is directly related to the 
relative abundance and stability of Npt2a in the apical membrane. The expression of 
Npt2a in the brush border membrane is heavily reliant on its interaction with the 
scaffolding protein NHERF-1 (sodium-hydrogen exchanger regulatory factor 1). As its 
name implies, NHERF-1 was originally identified for its role in the regulation of NHE3, 
but has since been identified as a protein with more global function than just regulation of 
sodium-hydrogen exchange
45,76
. Of the population of Npt2a present in the apical 
membrane of the proximal tubule, approximately 35-50% is bound to NHERF-1, and this 
interaction stabilizes Npt2a in the membrane and prolongs its retention there
77
. NHERF-1 
contains two PDZ domains – a conserved motif among scaffolding proteins that is crucial 
for its interaction with other proteins. Mutation analyses have shown the PDZ-1 domain 
of NHERF-1 to be critical not only for NHERF1-Npt2a associations, but also for 
regulated membrane expression
50
. As an indication of its biological importance, the 
NHERF-1 PDZ domain is highly conserved across species
50
, and serves as a regulatory 
target for several hormones, including PTH. NHERF-1 assembles a complex of proteins 





, and stabilizes the apical expression of those complexes through its interaction 
with the cytoskeleton
79
. Accordingly, NHERF-1 is also required for maximal PTH-
responsive inhibition of phosphate uptake
80
. In addition to the assembly of the PTH 
receptor complex, however, NHERF-1 also augments phosphate uptake inhibition by 8-
Br-cAMP, PMA, and forskolin (activating PKA, PKC, and adenylyl cyclase, 
respectively), indicating a role for NHERF-1 in PTH receptor signaling beyond the 
assembly of the PTHR1 complex
80
. 
PTH-stimulated endocytosis of Npt2a occurs through the phosphorylation of a 
serine residue in the PDZ domain of NHERF-1
77
, which induces the rapid dissociation of 
Npt2a from NHERF-1. Maximal disassociation occurs 30 to 40 minutes following PTH 
stimulation
32
. Whereas Npt2a undergoes rapid endocytosis in response to PTH, NHERF-
1 remains present in the membrane, as an important regulator for other ion transporters 
and protein complexes not involved in phosphate transport
32
. Following endocytosis to 
the endosomal compartment, Npt2a is targeted to lysosomes for degradation
81,82
. Re-
insertion of Npt2a back into the apical membrane following removal of the PTH stimulus 
requires de novo synthesis, and thus takes several hours before new Npt2a begins to 




Discrepant effects of acute versus chronic PTH 





 in acutely versus chronically PTH-treated Sprague-Dawley rats. To 
mimic the conditions of hyperparathyroidism, the rats were administered exogenous PTH 
(5 μg PTH/kg body weight) for either 6 hours (acute exposure) or 4 days (chronic 
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exposure, injected once daily). In comparison to saline-treated rats, both acutely and 
chronically treated rats displayed significantly decreased expression of Npt2a (Figure 3A, 
next page), as opposed to the alpha subunit of the sodium pump, which showed no 
significant change in expression between control and PTH-treated kidneys (Figure 3B). 
In addition to studying PTH-regulated proteins in the Sprague Dawley rat kidney, 
we also explored the chronic regulation of membrane proteins in a cell culture model of 
the proximal tubule, the opossum kidney (OK) cell, as described in Chapter IV Methods. 
OK cells were treated with either 2h PTH to mimic acute PTH, or 3d PTH (media 
replaced daily) to mimic chronic PTH stimulation. Brush-border membranes (BBM) and 
basolateral membranes (BLM) were isolated following PTH treatment, and protein 
expression was quantified by Western blot. As shown in Figure 4A (page 19), treatment 
of cells with PTH produced a rapid and significant reduction in Npt2a BBM expression, 
and this effect was sustained with chronic PTH. Expression of NHE3 did not change with 
acute PTH, and actually displayed a significant increase with chronic PTH. Neither 
NHERF-1 (Figure 4A) nor PTH receptor (PTHR1, Figure 4B) BBM expression changed 
with either acute or chronic PTH stimulation. Isolation of basolateral membranes from 




-ATPase also did 

















Figure 3: Effect of acute and chronic PTH on proximal tubule proteins. Four-
micrometer-thick sections of Sprague Dawley rat kidneys were prepared as described in 
Chapter IV Methods. Rats were treated with either vehicle, 6h PTH (5 μg/kg body 
weight), or 4d PTH (5 μg/kg body weight, administered daily). Expression of (A) Npt2a 




-ATPase α-subunit was determined by immunohistochemistry, as 
described in Chapter IV Methods. Representative picture of control or PTH-treated 
kidney is shown (n=3). 
 
 




































































Figure 4: Effect of PTH on BBM and BLM protein expression in proximal tubule 
cells. (A) OK WT cells were treated with 100nM PTH(1-34) and brush-border 
membranes (BBM) were isolated as described in Chapter IV Methods. Proteins were 
separated by SDS-PAGE and visualized through chemiluminescence on X-ray film. 
Bands for Npt2a, NHE3, and NHERF-1 were normalized as a ratio of β-actin band. * and 
*** are indicative of P <0.05 and P <0.001, respectively, versus control, as determined 
by one-way ANOVA (n=4). (B) Western blot showing expression of the PTHR1 in BBM 










To address the potential mechanism of the chronic down-regulation of Npt2a by 
PTH, we next examined the effect of PTH on the mRNA expression of both Npt2a and 
NHE3. As shown in Figure 5A, NHE3 mRNA expression is unaffected by 6h PTH, 
whereas Npt2a mRNA expression (Figure 5B) displayed a significant reduction at both 
the 6h (acute) and 4d (chronic) time points. 
FIGURE 5 
 
Figure 5: Effect of PTH on Npt2a and NHE3 mRNA expression. OK cells were 
treated for 6h or 3d with 100 nM PTH. As described in Chapter IV Methods, RT-qPCR 
was performed to quantitate (A) NHE3 mRNA expression in response to PTH (n=3), or 
(B) Npt2a mRNA expression in response to PTH (n=4). * is indicative of P < 0.05, as 
calculated by one-way ANOVA. 
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We observed no change in NHE3 BBM expression with acute PTH, and an 
increase with chronic PTH. While PTH is classically known to inhibit sodium/hydrogen 
exchange at the apical membrane, Yang et al. demonstrated that acute PTH induces that 
downregulation not through endocytosis of the transporter but instead through the 
redistribution of NHE3 to the base of the microvilli, where it is less active
84
. We showed  
that neither acute nor chronic PTH has an effect on NHERF-1 BBM expression, 
consistent with work previously demonstrated by Weinman et al.
32
. Previous data 
reported by our lab demonstrated that acute PTH-mediated downregulation of the 
expression and activity of the sodium pump desensitizes with chronic PTH
85
. In OK cells, 




-ATPase expression after 2h PTH treatment, 
although this was not significant. In rat renal cortex, we were unable to observe through 









-ATPase is endocytosed to sub-membrane compartments in response to PTH, and 




-ATPase expression with 6h and 4d PTH may not 
accurately reflect the changes in distribution of the protein in response to PTH. 
The results of the qPCR studies suggest distinct mechanisms of transporter 
regulation by PTH in the proximal tubule. PTH acutely downregulates NHE3 through 
NHE3 phosphorylation and subsequent redistribution to the base of the microvilli
84,86
, 
and this effect appears to desensitize with chronic PTH. We observed no effect of PTH 
on NHE3 mRNA expression.  In contrast to PTH-mediated NHE3 regulation, PTH 
induces a rapid reduction in Npt2a BBM expression through endocytosis and lysosomal 
degradation of the transporter, and this suppression of Npt2a expression is sustained with 
chronic PTH. Here we report preliminary evidence that Npt2a mRNA reduction is a 
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potential mechanism for the acute and chronic hypophosphatemic effect of PTH. The 
experiments detailed within this chapter provide support for the idea that chronic 
regulation of Npt2a by PTH occurs at the mRNA level. The subsequent studies outlined 
within this dissertation build upon these findings, expand our current understanding of 
Npt2a regulation by PTH, and provide a basis for the further exploration and study of 





















HYPOTHESIS AND SPECIFIC AIMS 
 
Overall Aim 
The work detailed within this dissertation elucidates three aspects of the 
mechanism by which parathyroid hormone regulates Npt2a mRNA within renal proximal 
tubules. Preliminary data addressing this physiological process has shown that PTH 
regulation of Npt2a is unique, in that transcript levels of Npt2a in addition to protein 
expression are decreased in response to hormone stimulation. Aim 1 determines whether 
PTH affects Npt2a mRNA at the transcriptional or post-transcriptional level. Aim 2 
identifies the signaling pathways that contribute to PTH-mediated Npt2a mRNA 
downregulation. Lastly, Aim 3 characterizes the PTH-responsive phosphoproteome of the 
proximal tubule, with a focus on identifying PTH-responsive RNA-binding proteins and 
elucidating their role in PTH-mediated Npt2a mRNA downregulation. 
 
Hypothesis 
PTH induces sustained suppression of Npt2a by decreasing Npt2a mRNA levels 
To address this hypothesis, this work will examine three aspects of the 




Specific Aim I:  
Determine whether PTH affects Npt2a mRNA at the transcriptional or post-
transcriptional level 
Acute PTH treatment causes a host of protein expression changes in the proximal 
tubule, some of which persist with chronic PTH exposure while others desensitize. 
Whereas sodium/potassium pump and sodium/hydrogen exchange expression and activity 
experience a transient decrease in response to PTH, suppression of Npt2a persists with 
prolonged PTH. Npt2a promoter activity does not change with PTH. However, our data 
suggests the likely possibility that PTH regulates Npt2a transcript levels in addition to 
inducing Npt2a protein degradation. Therefore, we hypothesize that PTH decreases 
Npt2a mRNA at a post-transcriptional level. We will use kidneys from transgenic 
hyperparathyroid mice and opossum kidney cells to study the effects of PTH on Npt2a 
mRNA expression and stability. 
 
Specific Aim II:  
Identify the second messenger pathway responsible for the PTH-mediated effect on 
Npt2a mRNA 
The PTH receptor is a type II G protein-coupled receptor (GPCR) capable of 
coupling with several different G proteins. The PKA and PKC signaling pathways are the 
two main second-messenger pathways activated upon PTH binding to the PTH receptor. 
Both pathways contribute to the regulation of Npt2a at the protein level, but it is 
unknown which of these pathways contributes to the PTH-mediated decrease in Npt2a 
mRNA. We hypothesize that activation of the PKA pathway is required for mediating the 
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PTH-induced decrease in Npt2a mRNA. We will use the opossum kidney (OK) cell 
culture line to study the effects of both the PKA and PKC pathways on Npt2a mRNA 
levels. 
Specific Aim III: 
Characterize the PTH-responsive phosphoproteome in proximal tubule cells 
Based on the results of Aim 2, we determined that PTH produces Npt2a mRNA 
destabilization through both PKA- and PKC-dependent mechanisms. Therefore, we aim 
to characterize the PTH-responsive phosphoproteome in the OK cell, with a focus on 
identifying RNA-binding proteins that are regulated by PTH. We hypothesize that PTH-
mediated Npt2a mRNA destabilization is dependent on upregulated expression and/or 
phosphorylation of an RNA-binding protein. We will use a proteomic approach to 
identify possible protein mediators of the PTH response, focusing on differential 





















The story of parathyroid hormone and renal phosphate reabsorption is an old one, 
and yet an incomplete one. Decades of research dating back to the 1920s detail the effects 
of PTH on proximal tubular reabsorption of the filtered load of phosphate
87
. The process 
by which PTH regulates Npt2a protein expression has been extremely well studied, and 
the kinetics of the hormone response have been determined down to the minute. In the 
bloodstream, circulating PTH has a half-life of approximately five minutes
88
, which 
suggests that under normal circumstances, the effects of PTH are rapid and short-lived. 
However, pathophysiological conditions such as primary hyperparathyroidism produce 
sustained elevated serum PTH levels that produce prolonged effects – most notably on 
serum phosphorus, calcium, and vitamin D levels. As previously discussed, the clinical 
manifestations of prolonged PTH stimulation show evidence for a mechanism of chronic 
down-regulation of proximal tubular phosphate reabsorption apart from the regulation of  
apical membrane protein expression of Npt2a. Considering the cellular energetics of 
constitutively transcribing, synthesizing, and trafficking Npt2a to the apical membrane,
27 
 
only to be immediately pulled back into the lysosomes and degraded, it is unlikely that 
PTH affects Npt2a expression solely at the protein level. 
Preliminary data by our lab suggest that PTH is capable of regulating Npt2a at the 
mRNA level. This finding is novel, and opens the door to exploring actions of PTH on 
the proximal tubule previously unconsidered. Decreased mRNA expression of a gene can 
be produced by two general mechanisms: (1) decreased transcription, or (2) decreased 
mRNA stability. While limited studies on the effect of PTH on either of those 
mechanisms for Npt2a regulation have been performed, Npt2a has been shown to be 
regulated at the transcriptional and post-transcriptional level by several other factors. 
 
Npt2a gene expression 
 In discussing the potential mechanisms for regulation of Npt2a mRNA 
expression, it serves to examine elements of gene structure and function that are already 
known. The human Npt2a gene is present on Chromosome 5 and has been well 
characterized by several laboratories
89
. Both the human and the mouse Npt2a genes were 
initially cloned and characterized in 1996 by Hartmann et al.
90
 The human Npt2a gene is 
approximately 14 kb long, with 13 exons and 12 introns
90,91
. Within the gene promoter 
region are CAAT and TATA boxes that together with the sequence of exon 1 drive gene 
transcription. Additionally, within both the human and murine genes, the translation 
initiation site is found within exon 2
90
.  
 The promoter region of the Npt2a gene has several cis-acting elements that 
govern its transcription. The transcription initiation site was identified as an adenosine 
residue 57 base pairs upstream of the 3’ end of the first exon (44 base pairs long), with 
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the TATA box 28 bp still upstream from that
91
. Further upstream of the TATA box in the 
5’ flanking region of the Npt2a gene, there are several cis-acting elements, including a 
cAMP responsive element, as well as binding sites for the transcription factors AP-1, AP-
2, and Sp1
91
. This 5’ flanking region of the NpT2 gene also contains a Vitamin D 




Npt2a promoter function is influenced by several factors. Basal rates of Npt2a 
transcription are affected by internal factors, including NHERF-1, as well as external 
factors such as vitamin A, vitamin D, and thyroid hormone. Basal levels of vitamin D 
appear to maintain juxtamedullary expression of Npt2a, as deficiency of vitamin D leads 
to decreased Npt2a mRNA and protein expression that is restored upon administration of 
vitamin D. In vitamin D-deprived rats, administration of vitamin D increases Npt2a gene 
promoter activity, leading to increased Npt2a mRNA and protein expression
92
. However, 
this is thought to be a weak effect, as increased vitamin D stimulation fails to elicit 
physiological effects in phosphate reabsorption beyond baseline uptake
6
. Vitamin A has 
also been shown to play an important role in Npt2a gene expression. Retinoic Acid 
Response Elements (RAREs) were identified within the promoter of the Npt2a gene by 
Masuda et al.
93
, who discovered that a deficiency in vitamin A induces increased renal 
phosphate excretion through down-regulation of both the Npt2a and Npt2c genes. 
NHERF-1, the regulatory protein important for Npt2a protein maturation and membrane 
localization, has also been shown to be important for the expression of the Npt2a gene, as 
demonstrated by Khundmiri et al., who showed that OK cells lacking NHERF-1 
expressed less Npt2a mRNA than their WT counterparts, and that Npt2a transcript levels 
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were restored upon transfection of NHERF-1-deficient cells with human NHERF-1 
constructs
94
. Lastly, thyroid hormone has also been identified as another factor that 
upregulates Npt2a gene expression by increasing its promoter activity. Ishiguro et al.
95
 
identified thyroid hormone responsive elements (TRE) within intron 1 of the Npt2a gene, 
and showed that T3 upregulates Npt2a gene expression in a renal cell-specific manner. 
Conversely, there are also several factors known to downregulate Npt2a promoter 
function. Elevated levels of bicarbonate/carbon dioxide independent of pH were shown 
by Jehle et al.
96
 to decrease Npt2a promoter function, and thereby decrease protein 
expression and phosphate transport. Vitamin D, in addition to activating Npt2a promoter 
activity, can also indirectly decrease Npt2a gene transcription, as vitamin D also 
upregulates fibroblast growth factor 23 (FGF23), a phosphaturic hormone. FGF23 
activates ERK1/2 signaling in the proximal tubule, and this results in phosphorylation of 
NHERF-1 with the subsequent endocytosis and degradation of Npt2a
57
. However, in a 
classic endocrine negative feedback loop, FGF23 decreases expression of 1α-
hydroxylase, leading to decreased levels of 1,25-dihydroxyvitamin D and also decreased 
expression of Npt2a
55,62
. Transgenic mice featuring overexpression of FGF23 present 





Post-transcriptional regulation of Npt2a 
 While several studies have demonstrated mechanisms for robust regulation of 
Npt2a expression at the gene level, others also demonstrate unique mechanisms for 
regulating Npt2a expression at a post-transcriptional level. Factors that have been shown 
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to modulate Npt2a mRNA stability include serum phosphate levels, glucocorticoids, and 
estrogen. Npt2a mRNA expression does not change in response to acute changes in 
dietary phosphate, but does however change in response to chronic changes in dietary 
phosphate
98–100
. Chronic low phosphate diets induce increased expression of Npt2a 
protein and mRNA in renal proximal tubules. Low serum phosphate induced by chronic 
low phosphate diets is accompanied by an increase in cytosolic calcium, and that increase 
has been shown to be critical for the upregulation of Npt2a transcript expression in 
response to low phosphate diets
101
. Tenenhouse et al.
99
 propose that this is due in part to 
post-transcriptional changes in Npt2a mRNA stability, as the increase in Npt2a protein 
expression produced by chronic low phosphate is much greater than the increase in Npt2a 
mRNA expression. Later, Moz et al.
3
 supported this tenet when they showed that 
hypophosphatemia induces increased binding of cytosolic proteins to the 3’ and 5’ UTR 
of Npt2a mRNA, thus increasing stability and translation.  Apart from regulation by 
serum phosphate, glucocorticoids decrease both Npt2a protein and mRNA expression
102–
104
, the latter due to effects independent of promoter activity. Estrogen has been shown to 
downregulate Npt2a mRNA expression in a manner independent of the estrogen receptor 
alpha isoform (ERα)
5
, potentially by decreasing transcript stability. Chronic Angiotensin 
II
105
 and acute inflammation in response to LPS administration
106
 have also been shown 
to post-transcriptionally modulate Npt2a expression. 
 
Evidence for a role of PTH in the regulation of Npt2a gene expression 
The vast majority of studies that have examined regulation of Npt2a by PTH have 
focused on regulation at the protein level. While it has been clearly demonstrated that 
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apical protein expression of Npt2a is greatly diminished in response to PTH, few studies 
have examined whether regulation of the transporter also occurs at the mRNA level, and 
those that have studied the effect of PTH on Npt2a mRNA expression have been limited 
and inconclusive. Kilav et al.
107
 were unable to demonstrate an effect of elevated PTH on 
Npt2a mRNA in a rat model of diet-induced hyperparathyroidism. However, the diet was 
only sustained for three weeks, and thus may not have provided sufficient time to observe 
changes in transcript levels. Confounding systemic effects from the diet itself may have 
also counteracted any potential downregulatory actions of the elevated PTH itself. In 
contrast to Kilav’s findings, three other laboratories have reported an effect of PTH on 
Npt2a mRNA. Kempson et al.
81
 showed that acute PTH treatment in 
parathyroidectomized rats decreased Npt2a mRNA expression by 30%. Independently, 
Moe et al.
108
 demonstrated that rats with hyperparathyroidism secondary to chronic 
kidney disease display a 50% reduction of levels of the Npt2a transcript. Friedlaender et 
al.
63
 reported modest inhibitory effects of PTH on Npt2a mRNA expression in PTH-
infused rats, which was augmented further when administered alongside vitamin D. 
Decreased transcript levels can generally be produced by either decreased gene 
promoter activity or by decreased mRNA stability, and work done by Hilfiker suggests 
that the inhibitory effect of PTH on Npt2a mRNA may be due to the latter. In their 
studies on the Npt2a gene promoter, Hilfiker et al.
109
 showed that PTH has no inhibitory 
effect on Npt2a promoter function. However, they did not examine Npt2a mRNA 
expression in response to PTH. While some controversy exists as to whether PTH 
regulates Npt2a mRNA levels, our preliminary data show a significant inhibitory effect. 
Since PTH has been shown to have no effect on Npt2a gene promoter activity, changes in 
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Npt2a mRNA levels in response to PTH most likely occur at the post-transcriptional 
level. Our preliminary data, as well as the aforementioned studies on Npt2a mRNA 
expression in response to PTH, indicate PTH is capable of regulating Npt2a beyond the 
protein level.  What has not been defined is the mechanism(s) for the PTH-mediated 
decrease in Npt2a mRNA. Based on our preliminary data and literature review, we 
hypothesize that PTH decreases Npt2a mRNA at a post-transcriptional level. The studies 
outlined in this chapter build upon our novel finding that Npt2a mRNA expression is 


















METHODS AND MATERIALS 
 
Materials:  Bovine PTH (1-34) was purchased from Bachem Biosciences Inc. (King of 
Prussia, PA).  Antibody against mouse Npt2a was a generous gift from Dr. Moshe Levi 
(University of Colorado). Opossum Npt2a antibody was developed as described 
previously
110
. NHERF-1 antibody was a gift from Dr. Weinman (University of 
Maryland)
76
. HRP-conjugated β-actin antibody was purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA). PTH receptor antibody was purchased from Covance 




 ATPase 1-subunit were 
purchased from Sigma-RBI (Natick, MA). Applied Biosystems PCR TaqMan Pre-
Developed Assay Reagents and Ambion MirVana miRNA isolation kits were purchased 
from Life Technologies (Grand Island, NY).  Immunohistochemistry reagents were 
purchased from Vector Laboratories (Burlingame, CA). Unless otherwise specified, all 
other chemicals were purchased from Sigma-Aldrich (St. Louis, MO). 
 
PTH-D1 mouse model: The PTH-D1 mouse is a transgenic mouse model of primary 
hyperparathyroidism, wherein the mouse develops gradual hyperplasia of the parathyroid 
glands due to parathyroid-specific cyclin D1 overexpression. In response to the 
parathyroid hyperplasia, these mice gradually develop biochemical and histological 
features of primary hyperparathyroidism, including elevated PTH, high serum calcium, 
and low serum phosphorus
111,112
. PTH-D1 kidneys were either frozen in liquid nitrogen 
for later analysis by qPCR and Western blot, or were fixed overnight in 
paraformaldehyde and embedded in paraffin for analysis by immunohistochemistry. 
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Kidneys from control mice of the same background strain as the PTH-D1 mice (FVB) 
and similar age were used for immunohistochemical and Western blot analyses. Control 
mRNA from 8-month-old FVB mice for qPCR experiments was a generous gift from Dr. 
Paul Epstein, University of Louisville. 
 
Cell culture: Studies involving time-dependent effects on Npt2a mRNA stability were 
conducted using the opossum kidney (OK) cell line, a continuous renal proximal tubule 
cell culture model derived from the Virginia opossum
113
. Importantly, the OK cell 
expresses PTH-responsive proteins, including the PTH receptor (PTHR1), coupled to Gs 
and Gq. Gs and Gq activate PKA and PKC, respectively, resulting in downregulation of 
Npt2a expression
114
. OK cells were cultured in Eagle’s Modified Essential Medium 
supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin in a 
humidified incubator at 37°C and 5% CO2. Unless otherwise noted, cells were grown to 
90-95% confluence on 6-well plastic plates (Corning, Tewksbury, MA) and serum-
starved overnight prior to treatment. 
 
Immunohistochemistry: Immunohistochemical staining of PTH-D1 and control FVB 




 ATPase α-subunit, NHERF-1, and the PTH 
receptor. Four-µm-thick sections were shaved from PTH-D1 and FVB kidneys fixed in 
paraffin blocks using a Leica RM2125RT microtome, and mounted on glass slides 
(Fisher, Pittsburgh, PA). Paraffin was cleared from slides by three washes with xylene 
(all washing steps were performed for five minutes unless otherwise noted).  Kidneys 
were rehydrated by ethanol gradient (100%, 95%, 70%) followed by two five-minute 
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water incubations and a final Tween-Tris-Buffered Saline (TTBS) wash. Slides were 
incubated in a low-pH citrate buffer solution (Vector Labs) for 20 minutes in a 95°C 
water bath to retrieve the antigen. Following a 20-minute cooling period at room 
temperature, slides were washed three times in water. Endogenous peroxidase was 
quenched with 3% H2O2, followed by three more washes with water and one wash with 
TTBS.  Slides were incubated in 2.5% horse serum in TTBS for 30 minutes at room 
temperature to block non-specific binding. Sections were then incubated overnight at 4°C 




 ATPase α-subunit (1:2000), 
NHERF-1 (1:1000), or PTHR1 (1:200), diluted with 1% BSA, 0.5% Triton X-100, and 
0.5% Tween-20 in water. Following primary antibody incubation, slides were washed 
three times with TTBS and incubated with biotin-conjugated secondary antibodies for 30 
minutes at room temperature. Slides were again washed three times with TTBS, 
incubated at room temperature for 30 minutes with Vectastain ABC reagent (Vector 
Labs), an avidin-biotin enzyme complex, followed by three more washes with TTBS.  
Sections were incubated with 3,3’-Diaminobenzidine (DAB, prepared according to 
Vector protocol) and monitored under a microscope.  Following visualization of 
chromatographic tubule staining, slides were quenched in water to stop the colorimetric 
reaction, and counterstained with methyl green.  Digital Images were obtained with a Q 
Color 5 camera attached to an Olympus BX51 microscope using Image pro 
software.  Immunostaining was quantified with Image-Pro 6.2 software (Media 
Cybernetics, Silver Spring, MD).  Five visual fields of cortex per kidney section were 
randomly selected and captured with a 40x objective.  Positive DAB staining was defined 
in a color profile by selecting a range of DAB staining intensities and the profile was 
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applied to all images collected.  Values for total staining area/field were obtained and 
presented as sum of staining area for each group. 
 
Brush Border Membrane (BBM) and Crude Membrane (CM) isolation: Brush-border 
membranes were isolated from OK WT cells grown on 0.1 µM transwell filters using the 
MgCl2 precipitation method. Following PTH or actinomycin D treatment, cells were 
washed twice with ice-cold PBS and scraped into 2mL tubes with 5mM Tris 50mM 
mannitol buffer pH 7.4. Cells were subjected to high-speed (20,500 rpm) homogenization 
with a PowerGen 125 polytron homogenizer (Fisher Scientific) for three 30-second 
intervals with an interval of 30 seconds between each stroke. Following homogenization, 
MgCl2 was added to the homogenate to a final concentration of 10mM and incubated on 
ice for 20 minutes with periodic vortexing. The homogenate was spun at 2000 rpm for 5 
minutes at 4°C, and the pellet was discarded. The resulting supernatant was spun at 
18,000 rpm for 45 minutes at 4°C to pellet brush-border membranes. The pellet was 
resuspended in 5mM Tris 300mM mannitol buffer pH 7.4. For crude membrane isolation 
from PTH-D1 and FVB mouse kidneys, minced kidney cortex was first homogenized in a 
glass Teflon homogenizer with ten complete strokes. The homogenate was then subjected 
to high-speed homogenization as described above, without MgCl2 precipitation, followed 
by a low-speed and a high-speed spin. 
 
Protein determination: Protein concentration of BBM and CM preparations was 
determined using a bicinchoninic acid (BCA) protein kit (Sigma) using bovine serum 
albumin (BSA) as a standard. 
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Western blot analysis: Following protein estimation, equal amounts of membrane 
proteins were heated in Laemmli buffer at 95°C for 5 minutes to denature proteins. 
Protein samples were separated on a 10% acrylamide gel by SDS-PAGE, and then 
transferred to a nitrocellulose membrane for immunodetection. Nitrocellulose blots were 
incubated in TTBS containing 5% milk at room temperature for 1 hour in order to block 
nonspecific binding to the membrane. Membranes were then incubated with primary 
antibodies diluted in 5% milk in TTBS overnight at 4°C on a rocker. Following overnight 
incubation, membranes were washed with TTBS three times for five minutes and once 
for 15 minutes. Membranes were then incubated in HRP-conjugated secondary antibodies 
diluted in 5% milk in TTBS for 1 hour at room temperature, followed by another round 
of TTBS washing. Bands were detected by chemiluminescence (Pierce), and visualized 
on X-ray film. 
 
Isolation of total RNA: OK cells were processed to isolate total RNA according to the 
manufacturer’s instructions (MirVana miRNA isolation kit, Life Technologies, Grand 
Island, NY). RNA concentrations were quantified at 260 nm wavelength with 280 nm 
wavelength as reference. For isolation of RNA from mice, kidney cortex from PTH-D1 
mice was dissected from decapsulated kidneys and homogenized with a pestle in 
MirVana lysis buffer. Once homogenized, total RNA was isolated as described above. 
 
Quantitative real-time PCR:  1 μg of RNA was reverse-transcribed to cDNA using a Bio-
Rad MyCycler thermal cycler with the High Capacity RNA-to-cDNA Master Mix system 
(Applied Biosystems, Foster City, CA) in a reaction volume of 25 μL.  Reverse 
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transcription was carried out at 25°C for 5 min, 42°C for 45 min, and heat inactivated at 
85°C for 5 min.  Resulting cDNA was diluted four-fold prior to PCR, to a final volume of 
100 μL. 5 μL of diluted cDNA was PCR-amplified using FAM detection and TaqMan 
Gene expression system with 50 nM Npt2a primers.  18S rRNA was used as a control 
house-keeping gene reference.  For OK cells, Npt2a forward primer sequence was 5’- 
TCTGAGAGTGCTGATGTACCTAAGT-3’, and reverse primer sequence was 5’- 
AGGTACTCATCCAACACCAGGTAT-3’.  Real-time PCR was then conducted in an 
Applied Biosystems 7500 Real Time PCR System with thermocycling setting of 50°C for 
2 min, 95°C for 10 min, and 40 repeats of 95°C for 15 sec followed by 60°C for 1 min.  
Relative quantitation was achieved by normalizing to 18S rRNA reference values, as 
detected through FAM-MGB, and by calibrating to control cells using the 2
-ΔΔCt
 method 
as described in Applied Biosystems User Bulletin 2: Rev B. For mouse RNA samples, the 
ΔCT value was determined using 18S and ΔΔCT values determined using the ΔCT value 
from one FVB control as the calibrator for all samples (FVB and PTHD1).  For OK cell 
time course, the Npt2a mRNA levels were expressed relative to control (t=0) that was set 
to 100 for each experiment.  The average values from 4-6 independent experiments +/- 
SEM were plotted on a semilogarithmic scale and the half-life calculated by linear 
regression. 
 
Luciferase reporter gene assays: Npt2a promoter-luciferase reporter gene constructs 
(Npt2a-luc) containing -208 bp and -4700 bp were a generous gift of Heine Murer
115
.  
Npt2a-luc or pGL3-basic and Renilla luciferase reporter (pRL-TK, Promega) plasmids 
were cotransfected into OK-WT cells using Lipofectamine 2000 (Invitrogen). At 24 h 
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post-transfection, firefly luciferase and Renilla luciferase activities were determined 
using Dual-Glo Luciferase Assay System (Promega) according to the manufacturer's 
protocol. The Luciferase:Renilla ratios were determined per well.  For each independent 
experiment the cells were transfected in triplicate, and the values averaged. 
 
Statistics:  Data are shown as mean ± SE.  The n values represent the number of 
independent experiments.  Each experiment was performed in triplicate unless otherwise 
indicated.  P values were calculated by Student’s t-test or by one-way or two-way 
ANOVA, followed by Bonferroni analysis using GraphPad Prism software.  A P value 
<0.05 was a priori considered statistically significant.  
 
Ethical aspects of the proposed research: All animal studies in this dissertation were 
performed in accordance with the University of Louisville IACUC. Radiation 
experiments throughout this dissertation were performed under the auspices of the 
University of Louisville Radiation Safety Office. We have reviewed the literature and 
concluded that our proposed research does not needlessly duplicate previous studies. We 
have examined every aspect of our research plan for biohazards and have made all the 










Part 1: Effect of chronic primary hyperparathyroidism on renal tubular proteins 
 
To examine the effect of PTH on Npt2a mRNA expression in vivo, studies were 
conducted using a transgenic mouse model of chronic primary hyperparathyroidism, the 
PTH-D1 mouse. This model was developed and characterized by Andrew Arnold’s 
laboratory, and features parathyroid-specific cyclin D1 overexpression, leading to the 
gradual development of primary hyperparathyroidism
111,112
. The 8-month-old PTH-D1 
model of chronic hyperparathyroidism is advantageous due to the animal’s endogenous 
over-production of PTH, eliminating the need for invasive thyroparathyroidectomy 
surgery and administration of exogenous PTH, thus relieving stress on the animal and 
mimicking more closely the human condition of primary hyperparathyroidism. Consistent 
with the clinical features of primary hyperparathyroidism, these animals develop elevated 
serum PTH and Ca
2+
 and decreased serum Pi
111
. 
IHC using kidneys from control and PTH-D1 mice confirmed that the PTH-D1 
mice display chronically reduced expression of Npt2a in the proximal tubule in 





-ATPase α1 subunit, PTHR1, and NHERF-1, however, did not differ (Figures 6B 
– 6D) between the two animal models. Crude membranes isolated from kidney cortex of 




 α1 subunit 






Figure 6: Proximal tubule protein expression in response to chronic PTH. 




-ATPase α1-subunit, (C) 
NHERF-1, and (D) PTHR1 in control FVB and PTH-D1 mouse kidneys. (E) Quantitation 
of Npt2a IHC staining from (A). (F) Crude membranes were prepared from cortex of 





 ATPase α1-subunit expression. Images shown are representative (n = 6). * is 
indicative of P < 0.05, as determined by student’s t-test. 
42 
 
Renal proximal tubule Npt2a expression analysis of the PTH-D1 mouse is 
consistent with the biochemical characterization performed by Imanishi et al.
111
, 
confirming the utility of this mouse model for exploring mechanisms of chronic 
phosphate regulation by PTH. To address the mechanism for the chronic down-regulation 
of Npt2a by PTH, Npt2a mRNA expression in control versus PTH-D1 mice was 
examined. As shown in Figure 7, PTH-D1 mice express Npt2a mRNA levels 




Figure 7: Npt2a mRNA expression in PTH-D1 mice. RT-qPCR with mRNA isolated 
from control and PTH-D1 kidneys (as described in Methods) revealed an approximate 
50% decrease in Npt2a in hyperparathyroid PTH-D1 kidneys as compared to age-




Part 2: Time-dependent effects of PTH on Npt2a mRNA 
 
To further explore the effect of PTH to Npt2a mRNA levels, the opossum kidney 
cell culture model, a continuous cell line derived from the Virginia opossum, was used to 
study time-dependent effects of PTH on Npt2a mRNA levels. OK cells were treated with 
100nM PTH (1-34) from 30 minutes up to 24 hours. RNA was isolated as described in 
Methods, and reverse-transcribed into cDNA. Quantitative PCR was performed to 
measure Npt2a mRNA expression. PCR showed that PTH treatment caused a very rapid 
decrease in Npt2a mRNA, with an approximate 30% reduction observed after 30 minutes 
of PTH, reaching statistical significance at the 1h time point (Figure 8). Npt2a mRNA 
levels continued to decrease in response to PTH in a time-dependent manner, with an 
ultimate reduction of approximately 75% achieved by 24h PTH. As calculated by linear 





Figure 8: Npt2a mRNA expression in response to PTH in OK cells. RT-qPCR with 
mRNA isolated from OK WT cells treated with 100nM PTH (1-34) for times indicated. *, 




Part 3: Roles of transcription and translation in Npt2a mRNA stability 
 
 To compare the stability of Npt2a mRNA under basal conditions and after 
treatment with PTH, OK cells were treated with actinomycin D, an inhibitor of 
transcription, over the course of 12 hours. Npt2a mRNA displayed a time-dependent 
decrease (Figure 9A), which achieved significance by the 4-hour time point, and an 
ultimate reduction of approximately 60% was observed by the 12-hour time point. Under 
conditions of halted transcription, Npt2a mRNA displayed a 50% reduction after 8.6h, 
which is substantially longer than the amount of time required to achieve a 50% reduction 
in Npt2a mRNA during PTH treatment. To determine if the inhibitory effect of PTH on 
Npt2a mRNA expression involved transcription, OK cells were next pretreated with 
actinomycin D alone for 30 minutes, followed by combined treatment with actinomycin 
D and PTH. As shown in Figure 9B, the time-dependent decrease in Npt2a mRNA was 
blunted, only showing a significant decrease by the 4-hour time point. Treatment of OK 
cells with PTH while blocking transcription produced a curve very similar to that of 
actinomycin D alone, and was significantly different from the curve produced by PTH 
alone (Figure 9C). At the protein level, actinomycin D alone had little effect on brush-
border membrane expression of Npt2a (Figure 9D). However, inhibiting transcription 
while treating OK cells with PTH did not prevent PTH-mediated endocytosis and 
degradation of Npt2a from the apical membrane, indicating that PTH-induced Npt2a 










Figure 9: Role of transcription in Npt2a mRNA regulation. RT-qPCR with mRNA 
isolated from OK WT cells treated with (A) Actinomycin D (Act D, 1 µg/mL), or (B) 
combined PTH and Act D (with 30min Act D pretreatment), for times indicated. *, **, 
and *** are indicative of P < 0.05, 0.01, and 0.001, respectively, as calculated by one-
way ANOVA. (C) Comparison of time courses with PTH alone, Act D alone, and 
combined PTH + Act D treatment. * and ** are indicative of P < 0.05 and 0.01, 
respectively, between both Act D alone and PTH + Act D versus control. # is indicative of 
P < 0.05 for PTH + Act D versus control, as calculated by two-way ANOVA. (D) Western 
blot shows Npt2a BBM expression in response to PTH alone [P], Act D alone [A], or 




Similar to the previous experiment of inhibiting transcription in the presence of 
PTH, OK cells were next treated with cycloheximide, an inhibitor of translation, in the 
presence or absence of PTH. As shown in Figure 10, the inhibitory effect of PTH on 
Npt2a mRNA was blocked by cycloheximide treatment. Following 2h of combined PTH 
and cycloheximide treatment, Npt2a mRNA expression was only reduced by 
approximately 25%. This preservation of Npt2a mRNA in the presence of both 
cycloheximide and PTH was maintained after 6h of combined treatment, in which Npt2a 




Figure 10: Role of translation in Npt2a mRNA regulation. OK cells were treated with 
cycloheximide (Chx, 1 µg/mL) in the presence or absence of PTH. Cells treated with 
cycloheximide alone (Chx) or both cycloheximide and PTH (P + C) received a 30m 





Part 4: Effect of PTH on Npt2a promoter activity 
 
To confirm that the mechanism whereby PTH decreases Npt2a mRNA is post-
transcriptional, luciferase reporter assays were performed to determine whether PTH has 
any effect on Npt2a gene promoter activity. Luciferase reporter constructs featuring 
either full-length Npt2a promoter (4700 bp) or a truncated promoter (208 bp) that 
displays twice the activity as the full-length promoter were transfected into OK cells. 
These cells were then treated with PTH for 8 or 24 hours, and luciferase activity was 
calculated relative to Renilla as a transfection control. Reporter assays showed no effect 
of PTH on Npt2a promoter function with either the full-length promoter or truncated 
version (Figure 11). 
FIGURE 11 
 
Figure 11: Effect of PTH on Npt2a promoter function. OK cells were co-transfected 
with Npt2a full-length (4700 bp) or truncated (208 bp) promoter luciferase constructs, 
and Renilla constructs as internal control, as described in Methods. Luciferase values are 





 Here we provide evidence that PTH selectively produces a sustained reduction in 
Npt2a expression at the protein and mRNA level in the renal proximal tubule. In a mouse 
model of primary hyperparathyroidism, Npt2a expression remained suppressed while the 
sodium pump and the PTH receptor displayed no significant changes in expression. PTH 
stimulation of the proximal tubule induces the rapid endocytosis of Npt2a, followed by 
lysosomal degradation of the transporter, thus requiring de novo synthesis for the 
reinsertion of Npt2a back into the membrane. While PTH is a known regulator of Npt2a 
protein degradation, here we show that PTH also regulates the rates of de novo synthesis 
through its effects on Npt2a mRNA levels in the cell. In both hyperparathyroid models 
used in this study, PTH significantly and rapidly reduced Npt2a mRNA expression 
through post-transcriptional mechanisms. The Npt2a gene promoter has several cis-acting 
elements in it, including cAMP response elements, introducing the possibility that PTH-
stimulated cAMP signaling may regulate Npt2a promoter activity. However, we observed 
no effect of PTH on Npt2a promoter function, either at the 8h or 24h time point, so while 
Npt2a gene promoter function is regulated by several factors, PTH is not one of them. 
This observation is in accordance with previous studies published by Hilfiker et al.
109,116
. 
The luciferase reporter assays thus support the notion that the PTH-mediated decrease in 
Npt2a mRNA is a strictly post-transcriptional process. 
 Exploring further the mechanism behind the regulation of Npt2a mRNA by PTH, 
we found that the effect of PTH on Npt2a is dependent on both transcription and 
translation. We found the basal reduction of Npt2a mRNA to the 50% level required 8.6 
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hours, but PTH greatly reduced that time to just over 2 hours. Inhibiting transcription 
with actinomycin D while treating cells with PTH completely blocked the ability of PTH 
to destabilize the transcript. The dependence of PTH-mediated destabilization of Npt2a 
mRNA on transcription suggests two possibilities – either upregulation of a miRNA or 
upregulation of a protein is responsible for mediating the PTH response. Inhibiting 
translation with cycloheximide while treating OK cells with PTH showed that the PTH 
effect is also dependent on translation. While the rapid reduction of Npt2a mRNA is 
consistent with miRNA involvement, the observation that this is a cycloheximide-
sensitive mechanism indicates that enhanced protein synthesis, potentially of an RNA-
binding protein, is vital for this destabilization process. 
While this is the first report of protein synthesis potentially leading to altered 
Npt2a mRNA stability in response to PTH, previous studies have demonstrated that 
Npt2a mRNA stability is regulated in response to various stimuli through differential 
protein expression. In a study where hypophosphatemia increases Npt2a mRNA levels, 
Moz et al.
3
 showed that a low phosphate diet in rats induces post-transcriptional 
stabilization of Npt2a mRNA. In their model of hypophosphatemia, a low phosphate diet 
induced increased production of renal cytosolic proteins, and that these proteins had a 
protective effect on the Npt2a mRNA by binding to both the 5’ untranslated region 
(UTR) and 3’ UTR. Their work indicates that there is a cis-acting instability element in 
the protein-binding region of the 3’ UTR of Npt2a mRNA
3,117
, and that cytosolic proteins 
produced in response to hypophosphatemia bind to this region and stabilize the transcript. 
This influence of serum phosphate levels on Npt2a mRNA stability was also observed in 
another study of a distal tubule-specific Klotho knockout mouse. This knockout mouse 
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displays increased protein expression of Npt2a in the proximal tubule as a result of the 
Klotho deletion, and yet decreased levels of the Npt2a transcript, perhaps in response to 
the accompanying hyperphosphatemia
56
. Glucocorticoids, known downregulators of 
sodium-phosphate cotransport in the proximal tubule, have been shown to reduce both 
Npt2a protein and mRNA expression. Dexamethasone, a synthetic glucocorticoid, 
decreases Npt2a mRNA and protein abundance in a manner that is also dependent on 
both transcription and translation
102
. This study in conjunction with ours suggests the 
possibility that the characteristics of the specific proteins interacting with the 3’ UTR of 
Npt2a mRNA determine the fate of the transcript.  
Combined, these studies support the notion that the changes in Npt2a mRNA 
stability evoked by PTH are due to increased protein synthesis, particularly increased 
expression of RNA-binding proteins. This mechanism of post-transcriptional regulation 
of Npt2a by PTH is potentially unique to Npt2a alone, as we observed no effect of 
chronic PTH on the expression of other PTH targets, including the sodium-potassium 
pump and NHE3. In the studies described in this chapter, we have demonstrated that PTH 
induces rapid destabilization of Npt2a mRNA, and that this effect is dependent on 
transcription and translation. Based on these findings, we propose that PTH upregulates 
the expression of an RNA binding protein that enhances Npt2a mRNA degradation. 









Npt2a undergoes downregulation both at the protein level and the mRNA level in 
response to PTH through distinct mechanisms. PTH induces rapid destabilization of 
Npt2a mRNA through post-transcriptional mechanisms dependent on the upregulation of 

















SPECIFIC AIM II: PKA AND PKC CONTRIBUTE TO PTH-MEDIATED  
NPT2A MRNA DESTABILIZATION 
 
The PTH receptor signaling complex 
 
 In Chapter IV, we established that PTH induces rapid destabilization of Npt2a 
mRNA in the proximal tubule, and that this destabilization is sustained with chronic 
PTH. Exploring further the mechanism of PTH-induced Npt2a mRNA destabilization, the 
goal of the present chapter is to elucidate the signaling events that mediate this response. 
PTH signaling in the proximal tubule is elicited through its interaction with the PTH 
receptor type I (PTHR1). The PTH receptor is a member of the G protein-coupled 
receptor (GPCR) family, with seven transmembrane domains, an extracellular amino 
terminus, and an intracellular carboxyl terminus. The amino acid sequence of the PTH 
receptor is conserved across species, with PTHR1 cloned from rat osteoblasts displaying 
78% conservation to the opossum kidney PTHR1, indicating an important systemic role 
for the receptor
118
. PTH receptor expression has been identified in a wide array of tissues, 
including the uterus, gut ovaries, and liver, although expression of the PTHR1 in these 
tissues is thought to be more important for paracrine/autocrine signaling by the PTH 
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related peptide PTHrP, which also couples to the PTHR1
119
. The highest expression of 
the PTHR1 within the body is found in the bone and kidney. Within the kidney, PTH 




PTH receptors in the proximal tubule are expressed in both the apical and 
basolateral membranes
122
. The PTH receptor is a member of the class II GPCR family, 
and possesses the ability to activate several intracellular signaling pathways. It has been 
shown to couple to several G proteins, including Gs and Gq, leading to the subsequent 
activation of the cAMP/PKA and PLC/PKC pathways, respectively
4
. These 
characteristics of ligand-receptor signaling are preserved in cell culture models of the 
proximal tubule, including opossum kidney cells, where stimulation of the PTHR1 by 
PTH produces activation of two major signaling pathways: (1) the Gαs/adenylyl 





The signaling pathways activated by PTH are complex and cell-specific, and 
influence more than just renal phosphate transport. Although the PKA and PKC pathways 
are the primary pathways activated in the proximal tubule, PTH receptors throughout the 
body differ in their structural requirements for signaling pathway activation, particularly 
when it comes to phospholipase activation. Proximal tubular PTH receptors, for example, 
are capable of activating different phospholipases from the ones activated by distal tubule 
PTH receptors
120
. PTH receptors even within the same cell may differ in their G protein-
coupling capacities based on their distribution in the apical versus basolateral membrane. 
Early studies suggested that the PTH receptor in the proximal tubule coupled to distinct G 
proteins on the apical and basolateral membranes, with apical PTH1Rs thought to 
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activate PKC exclusively, whereas basolateral PTH1Rs activated both PKA and PKC
124
. 
However, Npt2a-GST pull-down experiments by Khundmiri et al.
125
 showed that Npt2a 
in the BBM of OK cells associates with AKAP79, PKA (both the catalytic and regulatory 
subunits), and the PTH receptor, and that AKAP-mediated activation of PKA was critical 
for downregulation of phosphate transport by PTH. While the aforementioned studies 
provide conflicting evidence for specific G protein coupling dependent on receptor 
localization, they nonetheless confirm the role of both Gs and Gq in mediating PTH 
signaling within the proximal tubule. 
Although the predominant signaling pathways activated by PTH include the 
cAMP/PKA and PLC/PKC pathways
118
, there are a number of other pathways that PTH 
has also been shown to activate, and these also appear to be tissue-specific. These include 
phospholipase A2 in osteoblasts and proximal tubules
126
, phospholipase D in distal 
tubules
120
, and the mitogen-activated protein kinase (MAPK) pathway in OK cells
127
. In 
addition to activating PKA, cAMP also activates another category of proteins known as 
exchange proteins directly activated by cAMP (Epac), which are guanine nucleotide 
exchange factors for the Ras GTPase family of proteins
128
. Epac1 and Epac2 are both 
expressed in the brush border of the proximal tubule
129
, and are known regulators of 












-ATPase activity and expression via extracellular signal-
regulated kinase (ERK)-mediated activation of PKC- and PLA2-dependent pathways
49,71
. 
Of the pathways activated by PTH in the proximal tubule, however, PKA and PKC 
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remain the most influential in mediating downstream phosphaturic effects of PTH 
signaling, and in that regard are the most highly studied. 
 
PTH-induced PKA signaling 
The PTHR1 is a potent stimulator of cAMP generation and PKA activity through 
its association with the G protein Gαs. As shown in Figure 12, when activated by ligand-
receptor interaction, Gαs activates the closely associated adenylyl cyclase (AC), an 
enzyme that rapidly catalyzes the formation of cyclic AMP (cAMP) from ATP. Within 
the AC family of proteins, nine isoforms have been identified, and the effects of those 
isoforms are dependent on “signalosomes” recruited by each specific isoform
130
. As 
studied in the rat nephron, AC isoforms II, III, VI, VII, and IX are expressed in the 
proximal tubule, with II, III, and IX confirmed through IHC to be expressed only in the 
apical membrane (IHC data unavailable for VI and VII)
131
. NHERF-1 has also been 
found to be important not only in the formation of the apical membrane signalosomes, 
but also for modulating the amount of cAMP generated in response to PTH stimulation, 
and its presence is mandatory for cAMP inhibition of NHE3
50,132
. 
Within 10 seconds of receptor binding, PTH induces a significant accumulation of 
cAMP
133
, which in turn activates protein kinase A (PKA) by binding to the regulatory 
subunits, causing dissociation from and activation of the PKA catalytic subunits, thus 
resulting in the phosphorylation of downstream targets. The cAMP signal is typically 
terminated through the actions of phosphodiesterases (PDEs) that hydrolyze cAMP to 
form 5’ AMP. In the case of PTH signaling, PTH also rapidly increases PDE activity in a 
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dose-dependent and PKA-dependent manner, providing a negative-feedback mechanism 
for the termination of PTH-induced cAMP signaling
134
. 
The dynamics of PTH signaling vary during acute versus sustained signaling. AC 
is a membrane-bound protein, and the cAMP produced by it is thus produced at the cell 
membrane. However, this site of cAMP generation is short-lived, as the PTHR1 
undergoes endocytosis shortly after stimulation by PTH. This series of events was 
originally thought to terminate receptor signaling, as association of β-arrestins with the 
internalized receptor would desensitize downstream signaling. However, more recent 
studies have demonstrated that, following endocytosis of the receptor, cAMP generation 
is sustained. Whereas the previous dogma held that cAMP accumulation occurred only at 
the cell membrane, studies by Ferrandon et al.
133
 challenge this notion, when they showed 
that PTH(1-34) was endocytosed to early endosomal compartments, where it not only 
remained associated with the PTHR1, Gαs, and AC, but continued to produce cAMP over 
a period of 20 minutes. In this manner PTH evokes sustained signal generation in the 
proximal tubule, even after removal of the original stimulus. 
 
PTH-induced PKC signaling 
 While the PTHR1 is well known to activate cAMP-dependent pathways by 
coupling to Gs, the receptor also couples to Gq and is thus a potent stimulator of 
phospholipase C (PLC)-dependent signaling. Following the activation of PLC by Gq, 
PLC cleaves membrane phospholipids such as phosphatidylcholine and 
phosphatidylinositol 4,5-bisphosphate (PIP2), producing the two signaling molecules 
inositol triphosphate (IP3) and diacylglycerol (DAG). Downstream activation of PKC 
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occurs through two processes, as shown in Figure 12. DAG directly binds to and activates 
PKC, whereas IP3 binds to ligand-gated calcium channels in the membrane of the 
endoplasmic reticulum. The subsequent rise in intracellular [Ca
2+
] produces activation of 
PKC in cooperation with DAG. In OK cells, PKC is maximally stimulated 60-90 seconds 
following activation of the PTHR1 by PTH
32
. In addition to this PLC-mediated  




Figure 12: PTH-receptor binding and intracellular signaling in the proximal tubule. 
Binding of the ligand to the receptor increases the affinity of the intracellular beta-gamma 
binding region of the C-terminal region of the PTH receptor for G proteins, resulting in 
their subsequent activation and initiation of downstream signaling cascades. Gαs activates 
adenylyl cyclase (AC), which increases intracellular [cAMP], resulting in activation of 
Epac and PKA. Gq activates phospholipase C (PLC), forming diacylglycerol (DAG) and 
inositol triphosphate (IP3). DAG directly activates PKC, whereas IP3 indirectly activates 
PKC by releasing Ca
2+




 activation of PKC, the PTHR1s expressed in human, mouse, and opossum kidneys are 
also capable of activating PKC through PLC-independent mechanisms
135
. 
PTH-induced signaling is heavily dependent on the interaction of the PTHR1 with 
accessory proteins. NHERF-1, required not only for apical membrane localization for 
Npt2a, is also crucial for the regulation of PTH receptor signaling and second messenger 
generation. In OKH cells, a clonal cell line of the OK WT cell that is deficient in 
NHERF-1, PTH produces robust levels of cAMP, but fails to stimulate phospholipase C 
and does not inhibit phosphate transport
80
. In cells that express PTHR1-NHERF-2 
complexes, stimulation by PTH potently activates PLC signaling while inhibiting AC 
through the simultaneous activation of inhibitory Gi/o proteins
136
. PTH is thus capable of 
producing tissue-specific effects in accordance with the specific receptor-protein 
interactions present within the tissue membrane.  
 
PTHR1 endocytosis and desensitization 
The cessation of GPCR signaling is generally dependent on removal of the 
stimulus and receptor desensitization through endocytosis of the receptor from the plasma 
membrane. GPCR desensitization is a process that normally requires receptor 
phosphorylation and/or ubiquitination, promoting the association of β-arrestins that stop 
receptor signaling. Resensitization thus usually requires a process of dephosphorylation 
and removal of β-arrestin binding. In response to PTH stimulation, the PTHR1 carboxy-
terminus becomes phosphorylated, promoting β-arrestin2 binding and receptor 
desensitization, followed by endocytosis to an internal compartment
137
. PTH induces a 
transient polyubiquitination of the PTHR1 by promoting coupled ubiquitination followed 
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by deubiquitination through the rapid upregulation of the deubiquitinating enzyme 
USP2
138
. Following receptor endocytosis and desensitization, GPCRs usually re-sensitize 
and recycle back to the plasma membrane, which for the PTHR1 occurs within 2h after 
PTH stimulation
138
. The PTHR1 is unique amongst GPCRs in that it does not require 




NHERF-1 association with the PTHR1 helps to prolong the expression of the 
PTHR1 in the plasma membrane and helps sustain PTHR1 signaling. Wang et al. found 
that NHERF-1 was crucial for preventing β-arrestin2 from interacting with PTHR1, as 
well as for maintaining the association of the PTHR1 with Gαs
137
. The presence of 
NHERF-1 in the apical and basolateral membranes also protects against receptor 
desensitization by prolonging the retention of the PTHR1 in the plasma membrane
140
. 
The Golgi apparatus also appears to play an important role in PTHR1 recycling, as 
internalized PTHR1 colocalizes with the Golgi, and disrupting the Golgi impairs PTHR1 
recycling
141
. In addition to its association with the Golgi, the PTHR1 has also been shown 
to traffic in and out of the nucleus, although the physiological function of this trafficking 




Pathways involved in Npt2a protein downregulation 
The studies examining the relative contributions of the signaling pathways to the 
regulation of Npt2a by PTH have been inconclusive at best. Activation of both the PKA 
and PKC pathways has been shown to downregulate expression of Npt2a at the apical 
membrane in proximal tubule cells
77,143
. Several studies using cell-based and animal-
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based models have demonstrated that the two signaling pathways both contribute to PTH-
mediated downregulation of Npt2a protein expression
29,80,123,144,145
, and the relative 
contribution of each pathway is still under debate. 
 Several studies support a principal role for PKA signaling over PKC signaling in 
the sustained downregulation of Npt2a by PTH. In mice that lack adenylyl cyclase 
isoform 6 (AC6), PTH-induced endocytosis and subsequent lysosomal degradation of 
Npt2a is absent
146
. Through the use of PTH analogues with selective signaling properties, 
Nagai et al. showed that the acute down-regulation of phosphate transport in response to 
PTH involves primarily the cAMP/PKA pathway
123
. Genetic studies in Npt2c KO mice 
expressing WT or PLC-signaling-deficient PTHR1 showed that the hypophosphatemic 
response to PTH in PLC-signaling-deficient Npt2c KO mice was only slightly impaired, 
suggesting that chronic downregulation of Npt2a by PTH is primarily reliant on non-PLC 
signaling pathways
51
. Support for this conclusion is seen in patients with type Ia or type 
Ib pseudo-hypoparathyroidism, wherein a mutation in renal proximal tubule Gαs results 
in proximal tubule-specific PTH-resistance, resulting in diminished phosphate excretion 
and hyperphosphatemia
147,148
. This clinical picture implicates a preeminent role for PKA 
in mediating downregulation of sodium-phosphate cotransport by PTH, as PLC/PKC 
pathway signaling, which is presumably unaffected by the mutation, cannot compensate 
for the loss of cAMP/PKA signaling. 
 Although several studies have implicated PKA as the primary mediator of the 
PTH phosphaturic response, other studies highlight the importance of PKC signaling over 
PKA signaling. Whereas Nagai et al.
123
 used PTH analogues to demonstrate a dominant 
role for PKA signaling, Carpenter et al.
149
 showed preservation of the phosphaturic 
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effects of PTH in the absence of cAMP generation, through the use of PTH analogues 
with Gq-specific-activating properties. In mouse renal proximal tubule cells, inhibition of 
PKC completely blunted the inhibitory effect of PTH on phosphate transport, while the 
phosphaturic effect was unaffected by inhibiting PKA
58
. These studies by Cunningham et 
al. suggest that the inhibitory effect of cAMP on phosphate transport is reliant on 
downstream PKC activation, which would partially explain the phosphaturic effects of 
PKA, but does not address the mechanism for PTH-resistant hypophosphatemia in 
patients with pseudohypoparathyroidism. The differences between these studies may 
highlight species discrepancies in the contribution of PTH-stimulated signaling pathways 
to the regulation of phosphate transport by PTH. 
 PTH also activates several other signaling pathways in proximal tubule, but their 
roles, both as independent contributors to Npt2a regulation as well as adjunctive to PKA 
and PKC, in the regulation of Npt2a are not well understood. For instance, FGF23, 
another major phosphaturic factor, decreases both Npt2a protein and mRNA abundance 
through MAPK-dependent-signaling in the proximal tubule
150
. Although the MAPK 
pathway is critical for FGF23-induced hypophosphatemia, which is independent of PKA 
and PKC activation, the role of MAPK in PTH- and dopamine-mediated inhibition of 
phosphate transport is unclear
58
. PI3 kinase and phospholipase A2 are additional 
signaling pathways known to be activated by PTH, but their role in regulating phosphate 
transport has not been thoroughly investigated. To date, the cAMP/PKA and PLC/PKC 





Modification of receptor coupling and signaling through PTH fragments 
PTH is a peptide hormone, which in the mature, secreted form is 84 amino acids 
in length. The first 34 amino acids (1-34) are the biologically active portion of the 
hormone, responsible for full receptor coupling and subsequent G protein recruitment and 
activation (see Figure 12)
135
. Deletion of select amino acids within the peptide hormone 
results in an incomplete coupling of the ligand to the receptor, and a subsequent 
incomplete activation of downstream signaling pathways. Thus, modification of the 
amino acid composition of PTH yields analogues with selective PKA- or PKC-activating 
properties. Within this chapter, the analogues PTH(1-31) and PTH(3-34) are used to 
preferentially activate the PKA and PKC signaling pathways in order to better define 
their contribution to PTH regulation of phosphate transport. 
PTH(1-31) has been suggested as a relatively cAMP-selective PTHR1 agonist that 
is deficient for both PLC-dependent and –independent PKC signaling
135
. Treatment of 
proximal tubular cells with PTH(1-34) and PTH(1-31) produces a similar rise in cAMP, 
indicating that the carboxy-terminal deletion of residues (32-34) does not interfere with 
Gs activation
135
. PTH analogues truncated at the C-terminus further than the 31
st
 residue, 
however, fail to stimulate cAMP accumulation
120
. In contrast to Gs stimulation, the C-
terminus (residues 32-34) was found to be critical for Gq signaling, as demonstrated by 
Jouishomme et al., who showed that the PTH(29-32) fragment is the smallest hormone 
fragment capable of stimulating PKC, and that the His32 residue is critical for this 
stimulation to occur
151
. Loss of the His32 residue thus prevents PTH from activating 
PKC. This property of His32-receptor coupling prevents PTH(1-31) from activating 
PKC, while preserving full adenylyl cyclase-stimulating capabilities. 
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Truncating PTH at the amino terminus by two amino acids yields the PTH 
fragment PTH(3-34). Whereas the carboxyl terminus is crucial for activation of PKC, the 
amino terminus is likewise crucial for the activation of PKA. PTH(3-34), devoid of the 
amino terminal residues necessary for Gs activation, selectively activates PKC through 
non-PLC-dependent mechanisms
152
, albeit less effectively than the full-length analogue, 
and notably does not activate PKA
135
. Whereas stimulation of the proximal tubule by 
PTH(1-31) fails to result in an increase of intracellular calcium, stimulation with PTH(3-
34) results in a partial increase, indicating a selective role for PTH(3-34) in the activation 
of PKC
120
. In the experiments outlined in this chapter, human PTH(1-31) is used as a 
selective PKA-activating agent, whereas bovine PTH(3-34) is used as a selective PKC-
activating agent. 
 
PTH signaling and Npt2a mRNA regulation 
The signaling studies of PTH-mediated downregulation of Npt2a expression have 
focused solely on the secondary messenger pathways that lead to protein endocytosis and 
degradation. The PTHR1 has been shown to undergo resensitization and recycling back 
to the plasma membrane, and the results from Specific Aim I demonstrated that PTHR1 
expression remained unchanged with chronic PTH stimulation. While no one has 
examined signaling events that lead to Npt2a mRNA destabilization, given the dynamics 
of PTHR1 signaling and the time frame with which those signals cease, we expect there 
to be some pathway conservation between chronic protein regulation and chronic mRNA 
regulation by PTH. Based on our results from Specific Aim I, we are proposing that the 
mechanism of PTH-mediated Npt2a mRNA destabilization involves upregulation of an 
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RNA binding protein. Studies in bone examining PTH-responsive induction of gene 
expression showed that PTH induces rapid upregulation of gene expression through the 
cAMP-PKA pathway
153
. Given the evidence for downregulation of Npt2a protein 
expression by PTH, and the sustained cAMP signaling generated by prolonged PTHR1 
stimulation, we hypothesize that PKA is the primary mediator of PTH-induced Npt2a 
mRNA destabilization. We will study PTH-related signaling events and their contribution 
to PTH-mediated Npt2a mRNA destabilization using the opossum kidney cell line, as 
previously established in Chapter IV, as a model of PTH-sensitive phosphate transport. 
We also previously established in Chapter IV a time course of PTH-mediated decrease in 
Npt2a mRNA that showed a rapid decrease in mRNA levels within 2h of PTH, achieving 
a plateau after approximately 8h of PTH stimulation. For the purposes of these 
experiments, we have defined acute PTH treatment as 30m to 2h, and chronic PTH as 6h 
and 8h. We have therefore chosen to study the effects on the PKA and PKC signaling 
pathways for times varying from 30m to 8h. We will use a three-pronged approach to 
elucidate the signaling mechanisms in PTH-mediated Npt2a mRNA destabilization. First, 
we will use PTH analogues that are selective for PKA or PKC activation. Second, we will 
use pharmacologic agents to directly activate either PKA or PKC. Lastly, we will inhibit 









METHODS AND MATERIALS 
 
Materials: Bovine PTH(1-34), human PTH(1-31), and bovine PTH(3-34) were purchased 
from Bachem Biosciences Inc. (Kind of Prussia, PA). Phorbol myristate acetate, 8-pCPT-
2′-O-Me-cAMP, and chlorpromazine were purchased from Sigma-Aldrich (St. Louis, 
MO). 8-bromo-cAMP, PKC inhibitor peptide, and H-89 were purchased from 
Calbiochem (La Jolla, CA). Applied Biosystems PCR TaqMan Pre-Developed Assay 
Reagents and Ambion MirVana miRNA isolation kits and were purchased from Life 
Technologies (Grand Island, NY). PKA and PKC activity assay kits were purchased from 
EMD Millipore (Billerica, MA). ATP[
32
P] was purchased from Perkin Elmer (Waltham, 
MA). Unless otherwise specified, all other chemicals were purchased from Sigma-
Aldrich (St. Louis, MO). 
 
Cell culture: Studies involving time-dependent effects on Npt2a mRNA stability were 
conducted using the Opossum Kidney (OK) cell line. OK cells were cultured exactly as 
previously described in Chapter IV.  Unless otherwise noted, cells were grown to 90-95% 
confluence on 6-well plastic plates (Corning, Tewksbury, MA) and serum-starved 
overnight prior to treatment. 
 
Protein determination: Protein concentration of OK cell nuclear-free lysates was 
determined using a bicinchoninic acid (BCA) protein kit (Sigma) using bovine serum 
albumin (BSA) as a standard. 
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Isolate of total RNA: RNA isolation was performed exactly as previously described in 
Chapter IV. 
 
Quantitative real-time PCR: Reverse transcription and qPCR were performed exactly as 
previously described in Chapter IV.  
 
Radioactivity assays: All steps were performed on ice unless otherwise indicated. 
Radioactivity assays for measurement of PKA and PKC activities were performed 
according to manufacturer’s protocol. Briefly, OK cells were treated with PTH analogues 
and/or PKA or PKC inhibitors as described in Results for times indicated. Cells were 
washed twice with ice-cold PBS, and lysed in buffer consisting of 5mM Tris-HCl 50mM 
mannitol, pH 7.4, and protease and phosphatase inhibitors. Cells were homogenized by 
15 passes through a 26 gauge needle. Nuclear-free lysates were prepared by centrifuging 
lysates at 750*g for 5 minutes, and discarding the pellet. 10 μL of cell lysate per 
condition was incubated in a microcentrifuge tube containing 40 μL of the reaction 
reagent mix (prepared according to manufacturer’s protocol) and 10 μL of the [γ-
32
P]ATP 
mixture. The kinase reaction took place in a 30°C water bath with shaking for 10 
minutes. The reaction was stopped by removing 25 μL of the reaction mixture and slowly 
pipetting the aliquot onto phosphocellulose paper. Papers were washed three times with 
0.75% phosphoric acid, followed by one five-minute wash with acetone. Papers were 
allowed to dry before being added to scintillation vials containing 3 mL of Econo-safe 
scintillation cocktail (RPI, Mount Prospect, IL). CPMs were determined using a Tri-Carb 
2100TR liquid scintillation counter (Perkin Elmer, Waltham, MA). CPM of negative 
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control samples containing no enzyme were used as background control. Specific 
Radioactivity (S.R.) was calculated by measuring the CPM of 10 μL of the [
32
P]ATP 
solution, and dividing that value by 5 nmoles ATP to yield units of CPM/nmole ATP. 
This value was converted to CPM/pmole ATP by dividing the S.R. by 1000. PKA and 
PKC activities were calculated by subtracting the background CPM (“B”) from each 




 = pmole phosphate incorporated into substrate peptide/min 
 
This value was further divided by the amount of protein loaded per sample. Each 
experiment was comprised of two individual samples per condition. Within each 
experiment, the data was normalized to the average of the controls, and reported as % 
change from control.  
 
Statistics:  Data are shown as mean ± SE.  The n values represent the number of 
independent experiments.  P values were calculated by Student’s t-test or by one- or two-
way ANOVA, followed by Bonferroni analysis using GraphPad Prism software.  A P 









Part 1: Effects of PTH analogues on Npt2a mRNA expression  
To examine the relative contribution of the PKA and PKC signaling pathways 
toward PTH-mediated Npt2a mRNA destabilization, OK WT cells were treated with PTH 
analogues that relatively selectively activate specific signaling pathways. OK cells were 
treated with 100nM PTH(1-31) to selectively activate PKA, or 1μM PTH(3-34) to 
selectively activate PKC, for up to 8h. The concentration used for PTH(1-31) was 
determined according to concentrations published in previous studies
135
, while the 
optimal concentration for PTH(3-34) was determined by performing dose response 
curves of stimulated PKA activity and selecting the concentration at which PKA activity 
showed the least increase. PKA and PKC activity assays were performed to confirm the 
selective pathway-activating properties of each analogue. As shown in Figure 13C, 
PTH(1-34) produced a 40% increase in PKA activity within 15m of treatment, which fell 
to a plateau of about 20% above baseline by the 2h and 6h time points. PTH(1-31) 
produced a 20% increase in PKA activity within 15m that was sustained after 2h of 
treatment. PTH(3-34) also increased PKA activation by less than 20% at 15m, but this 
effect was transient, decreasing to less than control levels with 6h treatment. Looking at 
PKC activation by the PTH analogues, PTH(1-34) potently stimulated PKC activity by 
approximately 50% at both the 15m and 2h time points, and increased further still to 
200% by 6h (Figure 13D). PTH(3-34) produced a modest 20% increase in PKC activity 
that was sustained after 6 hours of treatment. PTH(1-31) acute treatment induced a 






Figure 13: Effect of pathway-
specific PTH analogues on Npt2a 
mRNA. RT-qPCR with RNA 
isolated from OK WT cells treated 
with either (A) 100nM PTH(1-31) 
(n=5), or (B) 1μM PTH(3-34) (n=6). 
*** is indicative of P < 0.001 versus 
control. (C) PKA activity and (D) 
PKC activity stimulated by the PTH 
analogues (n=4). * is indicative of P 
< 0.05 as calculated by two-way 
ANOVA. (E) Comparison of the 
relative contribution of the PTH 
analogues to Npt2a mRNA degradation. * is indicative of P < 0.05, comparing (1-34) to 
both (1-31) and (3-34) at times indicated. # is indicative of P < 0.05, comparing (1-34) to 
(1-31) at time point indicated, as calculated by two-way ANOVA. 
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Statistical analysis by two-way ANOVA of PKA and PKC activation by the analogues 
revealed that only PTH(1-34) produced a statistically significant increase in PKC activity 
after 6h of treatment, and thus further experiments will be necessary to better differentiate 
between the kinase-activating properties of each analogue. While these analogues were 
not as specific in activating PKA or PKC as had been previously described, and although 
both analogues failed to stimulate each kinase as strongly as PTH(1-34), we nonetheless 
established that PTH(1-31) preferentially activates PKA whereas PTH(3-34) 
preferentially activates PKC. 
With the kinase activation properties of the analogues defined, we next 
determined the effect of the analogues on Npt2a mRNA expression. Over the course of 8 
hours, treatment with both PTH(1-31) and PTH(3-34) produced a time-dependent 
decrease in Npt2a mRNA levels, (Figures 13A and 13B), with an approximate 45-50%  
reduction from control levels achieved after 8h treatment with either analogue. Whereas 
treatment with PTH(3-34) produced no significant effect on Npt2a mRNA until the 6h 
time point, PTH(1-31) significantly decreased Npt2a levels within 2h of treatment. As 
shown in Figure 13E, both PTH(1-31) and PTH(3-34) decreased Npt2a mRNA to a 
significantly less degree when compared to that induced by PTH(1-34). 
 
Part 2: Effects of direct activation of PKA vs PKC on Npt2a mRNA expression  
To further define the contribution of the PKA and PKC signaling pathways to the 
PTH-mediated effect on Npt2a mRNA expression, OK WT cells were next treated with 
direct activators of the respective signaling pathways. To directly activate PKA, OK cells 
were treated with 10 µM 8-bromo-cAMP (8-Br), a cell-permeable cAMP analogue that is 
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resistant to degradation by phosphodiesterases. Selective Epac activation was achieved 
by treating OK cells with 8-CPT-2Me-cAMP (10 μM), a cAMP analogue that retains 
Epac- but not PKA-binding properties
154
. To directly activate PKC, OK cells were treated 
with 100nM phorbol myristate acetate (PMA), a diacylglycerol mimetic. Over the course 




Figure 14: Direct activation of signaling pathways. RT-qPCR was performed with 
RNA isolated from OK WT cells (as described in Methods) treated with either (A) 10µM 
8-Br-cAMP, (B) 100nM PMA, or (C) 10µM 8-CPT-2Me-cAMP, for times indicated. (A) 
** and *** are indicative of P < 0.01 and 0.001, respectively, versus control, as 
determined by one-way ANOVA (n = 6). (D) * and *** are indicative of P < 0.05 and 
0.001, respectively, for PMA versus 8-Br, and +++ is indicative of P < 0.001 for 8-CPT 
versus 8-Br, as determined by two-way ANOVA (n=6). 
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levels, comparable to that achieved with PTH alone, with an approximate 55% reduction 
from control levels achieved after 8h treatment with 8-Br (Figure 14A). Treatment with 
PMA for up to 8h, however, failed to produce a statistically significant effect (Figure 
14B). Treatment of OK cells with 10 μM 8-CPT-2Me-cAMP also resulted in no effect on 
Npt2a mRNA expression (Figure 14C). In comparing the effects of selective PKA, PKC, 
and Epac activation on Npt2a mRNA expression (Figure 14D), the data strongly suggest 
a preeminent role for PKA action mediating the effect of PTH on Npt2a mRNA. 
 
Part 3: Effects of select pathway inhibition on PTH-mediated Npt2a mRNA 
destabilization  
 To support the results of the PTH analogues and direct activation studies, and to 
assess the ability of PTH to affect Npt2a mRNA levels during the inhibition of the either 
the PKA or PKC signaling pathways, we next treated OK cells with either an inhibitor of 
PKA, H-89, or an inhibitor of PKC, PKC inhibitory peptide (PKCi), in the presence and 
absence of PTH(1-34), over the course of 6h. Cells were pretreated with inhibitor alone 
for 30m prior to combined PTH-inhibitor treatment for each time point, for a total 
treatment time of 6.5h. To confirm the effectiveness of H-89 and PKCi as inhibitors, we 
performed assays at 15m (with 30m pre-treatment) to determine the relative activity of 
the kinases under the conditions aforementioned. As expected, PTH increased both PKA 
and PKC activity (Figures 15C and 15D). H-89 alone resulted in a 35% reduction in basal 
PKA activity, and completely prevented the activation of PKA by PTH. Inhibiting PKC 
had no effect on PKA activity, but surprisingly also blunted the ability of PTH to activate 






Figure 15: Effect of PTH on Npt2a mRNA during selective pathway inhibition. (A) 
and (B) RT-qPCR with RNA isolated from OK WT cells was performed as described in 
Methods. Cells were treated with (A) H-89 alone or combined PTH and H-89, or (B) 
PKCi alone or combined PTH and PKCi, for times indicated. All conditions (except 
control) received a 30m pre-treatment of (A) H-89 or (B) PKCi alone. *, **, and *** are 
indicative of P < 0.05, 0.01, and 0.001, respectively, within time points indicated, as 
determined by two-way ANOVA (n=4). (C) PKA and (D) PKC activity assays were 
performed as described in Methods. Treatments shown were performed for 15m, with a 
30m inhibitor pretreatment in conditions where inhibitors were present. * and *** are 
indicative of P < 0.05 and 0.001, respectively, versus control, and +++ is indicative of P 
< 0.001 versus PTH, as determined by one-way ANOVA (n = 6). 
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whereas PKCi failed to inhibit either basal PKC activity or PTH-induced PKC activation. 
While we were unable to achieve suppression of PKC activation in the presence of the 
PKC inhibitor peptide following 15m PTH treatment, previous experiments showed that 
PTH-stimulated PKC activity continues to increase over a 6h period. Additionally, while 
we observed an approximate 15% increase in PTH-stimulated PKC activity while 
inhibiting PKC, this is much less than the previously observed 40% increase in PKC 
activity following 15m PTH(1-34) activity. Further experiments will be necessary to 
account for the discrepancies observed between the results of the analogue experiments 
and the kinase inhibition experiments, as well as to further examine the effect of the PKC 
inhibitor peptide at preventing later increases in PKC activity.  
The effect of PTH on Npt2a mRNA expression during selective pathway 
inhibition was examined next using relatively specific pathway inhibitors. As shown in 
Figure 15A, the inhibition of PKA by 1µM H-89 over the course of 6.5h had no 
significant effect on Npt2a mRNA expression. With PKA inhibited, PTH still produced a 
decrease in Npt2a mRNA, although this effect was delayed compared to the time course 
of PTH alone, indicating that PKA is important for the early phase of PTH-mediated 
Npt2a mRNA destabilization. OK cells were next treated with 10µM PKCi, a selective 
peptide inhibitor of PKC. As with the H-89 experiments, inhibiting PKC alone did not 
affect Npt2a mRNA expression (Figure 15B). However, the partial inhibition of PKC did 
not prevent the PTH-mediated decrease in Npt2a mRNA, with significant decreases still 
observed at the 1h time point, and continuing to the 6h time point, with an ultimate 
reduction of 55% achieved following 6h of combined PKCi and PTH treatment, similar 
to what was achieved with PTH alone. While it appears that the PTH effect on Npt2a 
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mRNA was not blunted by the inhibition of PKC, PKC activity assays at the 1h and 6h 
time points are required to confirm these results. 
 
 
Part 4: Effect of inhibition of endocytosis on PTH-mediated Npt2a mRNA destabilization  
Recent studies suggest that chronic PTHR1 signaling occurs with endocytosis of 
the PTH receptor producing sustained cAMP generation
133
. In addition to their findings 
that sustained PTHR1 cAMP signaling occurs from early endosomal compartments, 
Ferrandon et al. also demonstrated that blocking the endocytosis of the ligand-receptor 
complex diminished the length of cAMP generation from more than 20 minutes down to 
about five minutes
133
. To test whether this mechanism of PTH signaling influences Npt2a 
mRNA expression levels, OK cells were treated for 30m with chlorpromazine (CPZ), an 
inhibitor of clathrin-mediated endocytosis
155
, in the presence and absence of PTH for 2h. 
As shown in Figure 16, inhibiting endocytosis did not blunt the effect of PTH on Npt2a 
mRNA. 
FIGURE 16 
Figure 16: Effect of 
endocytosis inhibition on 
PTH-mediated Npt2a 
mRNA destabilization. RT-
qPCR with RNA isolated 
from OK WT cells treated 
with either 100nM PTH(1-34) 
for 2h, 40µM chlorpromazine 
(CPZ) for 2.5 h, or 30m 
chlorpromazine pretreatment 
followed by combined PTH 






 We examined the relative contribution of PTH-stimulated signaling pathways to 
the destabilization of Npt2a mRNA using three different approaches: (1) PTH analogues 
with relatively selective kinase-activating properties, (2) pharmacologic activators of 
PKA and PKC, and (3) selective pathway inhibition during PTH treatment. The results of 
these studies suggest that the signaling pathways involved in PTH-induced Npt2a mRNA 
destabilization are complex and perhaps intertwined. The pharmacologic studies support 
the notion that PKA signaling is more important for the early phase of the PTH-
stimulated decreased in Npt2a mRNA, as selective stimulation of PKA using three 
approaches produced an earlier onset decline in Npt2a mRNA than did selective 
stimulation of PKC (Figure 17). Use of the PTH analogues study demonstrated that 
neither the PKA-specific nor the PKC-specific analogue by itself was capable of 
producing the same degree of Npt2a mRNA destabilization as occurs with activation of 
both by the full peptide hormone, although each analogue ultimately accomplished a 
partial reduction. Interpretation of these results in hampered by the fact that neither 
analogue was either completely specific or as effective in activating the designated 
pathway as was PTH(1-34). Direct activators of PKA and PKC revealed more clear-cut 
results, with PKA activation by 8-Br-cAMP producing a pattern of Npt2a mRNA 
destabilization very similar to that of PTH(1-34), and PKC activation by PMA producing 
no significant effect. Use of the selective inhibitors of PKA or PKC during PTH 
stimulation produced results that were also more difficult to interpret, as neither inhibitor 




Figure 17: Summary of effects of selective PKA or PKC activation on Npt2a mRNA. 
(A) Studies in which PKA was activated (treatments with PTH(1-31) [+], 8-Br-cAMP 
[*], and PTH + PKCi) are shown compared to PTH(1-34) treatment. (B) Studies in which 
PKC was activated (treatments with PTH(3-34) [*], PMA [#], and PTH+H-89 [+]) are 
shown compared to PTH(1-34) treatment. * and *** (according to respective symbol) are 
indicative of P < 0.05  and 0.01, respectively, as determined by two-way ANOVA, versus 
PTH(1-34). 
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Despite these limitations, the studies do suggest a role for PKA in the early phases of 
PTH-mediated Npt2a mRNA destabilization, while PKC contributes to the later 
destabilization of Npt2a mRNA. 
The activity assays performed are consistent with the conclusion that the two 
pathways contribute differentially, depending on whether the PTH stimulation is acute or 
chronic. Whereas PKA activity increased with 15m of PTH(1-34) treatment, this 
activation decreased by the 2h and 6h time points, indicating an early role for PKA 
signaling. PKC activity also increased within the first 15m of PTH(1-34) treatment, but 
unlike PKA, continued to increase throughout the 2h and 6h time points. Taking this into 
account with the fact that the relatively PKC-specific PTH analogue PTH(3-34) failed to 
produce a decrease in Npt2a mRNA until the 6h time point, these results suggest a more 
prominent role for PKC in long-term PTH signaling. In agreement with this conclusion, 
Guo et al.
51
 recently established that the sustained hypophosphatemic response to PTH in 
mice is dependent on the PLC signaling pathway. In transgenic mice featuring a PTH 
receptor incapable of PLC activation, PTH was only able to transiently decrease serum Pi 
for two days, after which the hypophosphatemic response decayed. These results support 
our findings that PKC signaling contributes to the later stages of Npt2a mRNA 
destabilization, but is not required for early inhibition. 
It is interesting to note that Pi-depleted animals fail to produce a 
hypophosphatemic response to PTH administration, despite normal activation of PKA
156
. 
The authors of the study concluded that phosphate depletion inhibits cellular metabolic 
pathways that are independent of cAMP signaling, and that inhibition of those pathways 
is sufficient to completely blunt the phosphaturic actions of PTH. The signaling pathways 
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affected by PTH may have a common end effector, but they also have independent 
actions that may blunt the influence of the other signaling pathway, and PKA and PKC 
may thus be able to independently exert downregulatory effects on Npt2a mRNA. 
The studies in this chapter point to an early role for PKA and a late role for PKC, 
but it appears that activation of both are essential for achieving the full decrease in Npt2a 
mRNA elicited by PTH(1-34). When comparing the effects of the two truncated PTH 
analogues on Npt2a mRNA versus the original effect of PTH(1-34) (Figure 13E), an 
interesting dichotomy emerges. In the early phases of PTH signaling, both PTH(1-31) 
and PTH(3-34) fell significantly short of decreasing Npt2a mRNA levels to the extent 
that PTH(1-34) did. It is not until the later stages of PTH signaling, hours 6 and 8, that 
PTH(3-34) and (1-31) appear to catch up with the decreases elicited by (1-34). Part of 
PTH-induced PKA signaling is produced by sustained cAMP production following 
endocytosis of the PTHR1 complex. Inhibiting PTHR1 endocytosis is known to prevent 
the sustained production of cAMP in response to PTH
133
. We tested whether this 
sustained generation of cAMP by PTHR1 endocytosis affected PTH regulation of Npt2a 
mRNA by treating OK cells with chlorpromazine, an inhibitor of endocytosis, in the 
absence and presence of PTH. We observed that inhibiting endocytosis failed to prevent 
PTH-mediated Npt2a mRNA destabilization. Although we are unable to make any 
conclusive statements regarding the contribution of internalized PTHR1 signaling to the 
sustained decreased in Npt2a mRNA, these results suggest that the initial generation of 
cAMP by adenylyl cyclase is sufficient for producing sustained destabilization of Npt2a 
mRNA. 
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These studies suggest the possibility of cross-talk between PKA and PKC, with 
neither kinase working completely independently of the other. This is not the first time 
studies have supported this kind of signaling mechanism in the regulation of Npt2a 
expression. In studies of Npt2a protein downregulation by PTH, Cunningham et al. 
proposed a cross-talk-dependent mechanism, wherein PTH stimulates PKA, which in turn 
activates PKC in order to cause the ultimate endocytosis of Npt2a from the apical 
membrane
58
. Dopamine, another phosphaturic agent, also activates both PKA and PKC in 
the kidney through the D1 receptor, and has also been shown to elicit cross-talk between 
the two kinases. Yu et al.
157
 demonstrated that dopamine-mediated inhibition of NADPH 
oxidase involved cross-talk between PKA and PKCθ, with PKA activation preceding and 
facilitating PKC activation, and phosphorylated PKCθ mediating the resultant inhibition 
of NADPH oxidase. The activity assays we performed with the PKA and PKC inhibitors 
support this conclusion, in that H-89 prevented both basal PKA and PKC activity, as well 
as PTH-induced PKA and PKC activity, and thus PKA most likely plays an additional 
role in the activation of PKC mediated by PTH. 
Although PKA-dependent PKC signaling is one possible explanation for the 
contribution of the signaling pathways we observed, it does not fully explain the 
signaling mechanisms involved in PTH regulation of Npt2a mRNA. Whereas 
Cunningham et al. observed that inhibiting PKC completely abolished the 
downregulation of Npt2a, we observed preservation of PTH-induced Npt2a mRNA 
degradation during the inhibition of either pathway. Another possibility aside from kinase 
cross-talk is that there are multiple ultimate mediators of the mRNA destabilization, and 
PKA and PKC are each responsible for activating one arm of the multi-pronged cascade. 
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This idea was demonstrated by Azarani et al.
158
, who showed that both PKA and PKC 
could independently decrease NHE3 activity. In this case, Npt2a mRNA destabilization 
could be accomplished through the activation of several RNA-binding proteins that 
function as an RNA destabilizing complex, with individual RNA-binding proteins 
modified by either PKA or PKC. The current studies do not provide distinction between 
these two possibilities of kinase cross-talk or independent effects, and thus additional 
studies are required to further define the mechanisms of intracellular signaling leading to 
destabilization of Npt2a mRNA. 
The PKA and PKC pathways are the primary signaling pathways activated by 
PTH in the proximal tubule, but there are additional pathways also activated by PTH that 
should be considered. For example, cAMP activates PKA, but it also activates another 
signaling molecule, Epac. Activated Epac is a demonstrated regulator of some PTH-
sensitive proximal tubule transporters, including NHE3
159
. To rule out the potential 
involvement of Epac in Npt2a mRNA regulation, a cAMP analogue that selectively 
activates Epac was used to treat OK cells. In agreement with previous studies that found 
that selective Epac activation had no effect on Npt2a protein expression and function
58
, 
we found no evidence of Epac involvement in the regulation of Npt2a mRNA expression.  
The data presented within this chapter provide compelling evidence for the 
importance of both PKA and PKC signaling in the degradation of Npt2a mRNA, but the 
lack of total congruity in the results from the three approaches precludes making absolute 
conclusions on the relative roles of each pathway. Of the three studies performed to 
examine the relative contribution of the PKA and PKC signaling pathways towards Npt2a 
mRNA destabilization, two of the studies suggest a role for late PKC involvement, but 
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the direct PKC activation study did not support this conclusion. In the direct activation 
studies, we used PMA to directly activate PKC. We observed no effect of PMA treatment 
on Npt2a mRNA expression, and these results conflict somewhat with the PTH(3-34) and 
PKCi studies. However, phorbol esters have been shown to change OK cell morphology 
by inducing cell rounding, and these changes are not observed with PTH treatment
80
. 
Thus, while the conflicting PMA data obfuscates the implication for PKC involvement 
indicated by the other studies, unintended consequences of the use of PMA may be 
responsible for the lack of an observable effect on Npt2a mRNA. PMA also bypasses 
activation of PLC, which may activate non-PKC pathways that contribute to Npt2a 
mRNA destabilization. Additionally, we did not examine intracellular calcium signaling 
with the use of PMA nor did we measure stimulated PKC activity, and the absence of the 
initial calcium spike may have prohibited full activation of PKC, thus preventing PKC-
mediated regulation of Npt2a mRNA.  
We are proposing that the upregulated activity and/or expression of an RNA-
binding protein is the mechanism behind chronic downregulation of Npt2a by PTH. From 
the studies herein, we found that the PTH-mediated decrease in Npt2a mRNA is 
dependent upon both PKA and PKC signaling. Both of these pathways contribute to the 
end result of mRNA degradation, and either individually or synergistically produce the 
PTH effect. The dependence of the PTH-induced decrease in Npt2a mRNA on 
transcription and translation suggests that PKA or PKC signaling is involved in changing 
the activity and/or expression of transcription factors. Studies by Queiroz-Leite et al.
160
 
determined that PTH-mediated PKA and JAK/STAT signaling in OKP cells, a clonal cell 
line of the OK WT cell, changes the profile of transcription factor expression in the 
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nucleus. This change in transcription factor expression may change the expression of 
RNA-binding proteins that in turn influence Npt2a mRNA stability. Given that we know 
post-translational modifications produced by PKA and PKC activation mediate Npt2a 
mRNA destabilization, the next goal in examining the aspects behind regulation of Npt2a 
mRNA by PTH was to identify downstream targets that have undergone changes in 
phosphorylation in response to PTH, and how those targets relate to the control of 
phosphate reabsorption in the proximal tubule. Further studies addressing this hypothesis 
of the regulation of RNA-binding proteins in the proximal tubule by PTH and their 
effects on Npt2a mRNA are outlined in Chapter VI. 
 
CONCLUSION 
We conclude that PKA mediates the early phase of PTH-mediated Npt2a mRNA 
destabilization, whereas chronic down-regulation requires both PKA- and PKC-mediated 
mechanisms through an intricate, concerted interplay between PKA and PKC signaling, 






SPECIFIC AIM III: CHARACTERIZATION OF THE PTH-RESPONSIVE 




Activation of the PTH receptor initiates several intracellular signaling cascades, 
and the actions of kinases and exchange factors produce the collective PTH response. 
Although much work has been done over the past several decades to elucidate the end 
results of PTH stimulation in the proximal tubule, the molecular pathways leading to the 
downregulation of phosphate transport are still poorly understood. We previously 
established in Chapter IV that PTH destabilizes Npt2a mRNA in a rapid fashion that is 
dependent on both transcription and translation. In Chapter V, we determined that both 
PKA and PKC signaling contributes to this effect, with PKA acting early and PKC acting 
late to promote Npt2a mRNA decay. While PTH-induced signaling pathways may 
produce upregulated gene expression of specific RBPs, another possibility is that PKA 
and PKC directly phosphorylate decay-promoting RBPs that have a high constitutive 
turnover rate. If the latter were true, inhibiting transcription and translation would blunt 
PTH-mediated destabilization of Npt2a mRNA. Given the results of the two previous 
aims, we hypothesize that PTH-mediated destabilization of Npt2a mRNA is dependent on 
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increased phosphorylation and/or expression of an RNA-binding protein. Presently, the 
goal of the current chapter is to characterize the PTH-responsive phosphoproteome 
within the proximal tubule, and characterize PTH-responsive RNA-binding proteins that 
may mediate Npt2a mRNA decay. 
  
Regulation of mRNA expression 
Regulation of mRNA, and in particular mRNA stability, is a dynamic process that 
involves a host of auxiliary factors, from the cradle to the grave. As soon as transcription 
begins in the nucleus, the emerging RNA strand is met by proteins that modify the 
transcript. Capping enzymes add a modified base, 7-methyl guanosine, to the 5’ end of 
the transcript, a spliceosome complex removes introns, and the 3’ end undergoes an 
addition of a polyadenosine (poly(A)) tail that enhances stability
161
. Along with the 
recruitment of nuclear export proteins, this initial association of proteins with the RNA 
strand forms a particle termed a ribonuclearprotein (mRNP) complex. The mRNP 
assembly is then exported to the cytoplasm as an mRNA strand that is comprised of a 
capped 5’ untranslated region (UTR), followed by a coding region, and finally a 3’ UTR 
with a poly(A) tail. 
Most mRNA regulatory elements are found within the 5’ and 3’UTR regions, 
where the primary and secondary structures serve as scaffolds for the recruitment of 
various protein complexes. In the cytoplasm, unique proteins interact with both ends of 
the mRNA strand. At the 5’ end, the protein eIF4E binds the modified guanosine cap
161
. 
The 3’ poly(A) tail is bound by the poly(A) binding protein (PABP). The initiation factor 
eIF4G forms a link between eIF4E and PABP, thus joining the 5’ and 3’ ends of the 
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transcript and forming a closed-loop conformation. This closed conformation protects the 
ends of the transcript from exonucleolytic decay and enhances overall transcript stability. 
The 5’UTR has mostly been implicated in the control of translation, whereas the 3’UTR 
serves several other critical functions, including nuclear export, cytoplasmic localization, 
translational efficiency, and mRNA stability
162
. 
More than 90% of human genes undergo alternative splicing, and the highest site 
for variation produced by alternative splicing is within the 3’UTR, highlighting its 
importance in producing the highly differential spatial expression profiles of proteins 
within various tissues throughout the body
163
. Structures within the transcript itself, such 
as the poly(A) tail or specific nucleotide motifs, are termed cis-acting sequence elements, 
and these elements dictate the profile of trans-acting factors, such as miRNA and RNA-
binding proteins (RBPs), that bind mRNA and determine the fate of the mRNA strand. 
For instance, sequences within the 3’UTR may dictate the types of location-determining 
RBPs that regulate mRNA localization
162
, and these distinct localization patterns allow 
for more rapid and controlled responses to external stimuli. Apart from miRNAs and 
RBPs, another major category of trans factors that regulate mRNA stability is comprised 
of small non-coding RNAs (ncRNAs) such as small interfering RNAs (siRNAs) and 
microRNAs (miRNAs). These small molecules regulate gene expression through partial 
or complete complementary binding to sequences within mRNA. Near-complementary 
binding typically prevents translation from occurring, whereas full-complementary 






Protein-induced mRNA decay 
RNA destabilization leads to the decay of the mRNA strand, which can be 
initiated either from the ends of the transcript or within the strand via endonucleolytic 
cleavage
161
, and the rate of RNA decay is modulated by the specific cohort of RBPs 
interacting with the message. One of the most well characterized family of RBPs that 
determine mRNA stability bind to a specific cis-element called adenylate-uridylate rich 
elements (AREs)
161
. These ARE-binding proteins, or ARE-BPs, typically bind a AUUUA 
pentamer in a U-rich region anywhere from 40 to 150 nucleotides long
164
. ARE-BPs can 
bind a spectrum of AREs, however, including ones that lack the canonical AUUUA 
motif
165
. Signifying its importance as a regulator of gene expression, bioinformatic 
studies suggest that 5 to 8% of human genes contain ARE sequences
166
. 
HuR is a member of well-known family of proteins that bind AREs and promote 
message stabilization, either through competitive binding with destabilizing trans factors, 
or through enhanced interactions of PABP with the poly(A) tail to prevent 
deadenylation
161
. Other ARE-BPs, including the AU-rich factor 1 (AUF1) and the KH 
splicing regulatory protein (KHSRP), promote mRNA destabilization
161
. Although AUF1 
is most classically known as an RNA destabilizer, new evidence suggests that under 




The 3’ UTR of Npt2a mRNA 
Not much is known about the trans factors that regulate Npt2a mRNA stability. 
Moz et al. previously demonstrated that hypophosphatemia increases Npt2a expression 
through stabilization of Npt2a mRNA via increased protein binding to a 71-nucleotide 
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cis-acting instability element in the 3’UTR
117,168
. However, little work has been published 
since those studies that detail RBP regulation of Npt2a mRNA in response to 
physiological stimuli. The predicted secondary structure for the opossum 3’ UTR of 
Npt2a is shown in Figure 18, based on either the minimum free energy of the structure 
(Figure 18A), or the thermodynamic favorability (Figure 18B). Several RNA-binding 
proteins are predicted to interact with the 3’ UTR of Npt2a mRNA, including ones that 
modulate stability. As shown in Figure 18C, these RBPs include ELAVL1 (a synonym 
for HuR), the ARE-BP that confers stability to a transcript, as well as KHSRP, an ARE-
BP that is known to destabilize transcripts. Many of the RBP binding sites also overlap, 
indicating the possibility of competitive binding for those RBPs. 
 
The PTH-responsive phosphoproteome 
Little is known about the range of downstream targets regulated by PTH signaling 
in the proximal tubule. The earliest studies of the PTH-responsive phosphoproteome 
looked at phosphorylation events at the apical membrane that governed the regulation of 
phosphate transport in response to PTH
169
. The present studies outlined in this chapter 
seek to characterize the cell-wide phosphorylation events that occur in response to PTH, 
and how those changes may relate to the downregulation of Npt2a mRNA. In Chapter IV, 
we established that PTH induces a rapid decrease in Npt2a mRNA, with an approximate 
50% decrease after 2h of PTH stimulation. In Chapter V, we determined that during the 
early phase, PKA signaling appeared to predominate, while PKC signaling played a more 
prominent role during the later phases. We have therefore chosen to study the PTH-








Figure 18: Predicted secondary structure of the 3’ UTR of Npt2a mRNA. The 
sequence for the 3’ UTR of opossum Npt2a (obtained from Ensembl.org) was submitted 
to the Vienna RNA Websuite program for computational analysis
170,171
. (A) Predicted 
secondary structure based on minimum free energy. (B) Predicted secondary structure 
based on the thermodynamic favorability of the minimum total base-pair distance to all 
structures in the ensemble. Color scale indicates likelihood of base-pair interaction or, for 
unpaired bases, likelihood of being unpaired, with blue representing unlikely and red 
representing highly likely. (C) Map of likely RBP interactions with the 3’ UTR of Npt2a 





and/or expression of an RBP is the mechanism behind PTH-mediated destabilization of 
Npt2a mRNA, we have not yet identified any potential effectors of the decay response. 
Characterizing the PTH-responsive phosphoproteome will not only provide candidate 
RNA-destabilizing targets for further exploration of the aspects behind Npt2a mRNA 
destabilization, but it will also provide novel hypothesis-generating data for research 



















METHODS AND MATERIALS 
 
Materials: Bovine PTH (1-34) was purchased from Bachem Biosciences Inc. (King of 
Prussia, PA). Magnetic RNA-binding protein immunoprecipitation (Magna RIP) kits 
were obtained from EMD Millipore (Billerica, MA). Antibodies against KHSRP and 
Roquin-2 were purchased from Novus Biologicals (Littleton, CO). All other reagents 
were obtained from Sigma (St. Louis, MO) unless otherwise indicated. 
 
PTH-D1 mouse model: Kidneys from PTH-D1 and age-matched control mice, as 
described in Chapter IV Methods, were used for IHC analysis of KHSRP and Roquin-2 
expression. 
 
Cell culture: Studies involving differential RBP expression in response to PTH were 
conducted using the Opossum Kidney (OK) cell line. OK cells were cultured exactly as 
previously described in Chapter IV.  Unless otherwise noted, cells were grown to 90-95% 
confluence on 6-well plastic plates (Corning, Tewksbury, MA) and serum-starved 
overnight prior to treatment. 
 
Protein determination: Protein concentration of OK cell nuclear-free lysates was 
determined using a bicinchoninic acid (BCA) protein kit (Sigma) using bovine serum 
albumin (BSA) as a standard. 
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Liquid chromatography-mass spectrometry: OK WT cells were grown to confluence in 
T-75 flasks, serum starved overnight, and treated with either 100nM PTH(1-34) for 2h or 
MEM (as control). Following treatment, cells were washed twice with ice-cold PBS and 
lysed in a 5mM Tris 50mM mannitol buffer, pH 7.4, containing protease and phosphatase 
inhibitor cocktails. Cells were homogenized by 15 passes through a 26G needle, and 
nuclei were discarded by centrifuging the samples at 750*g for 5min and retaining the 
supernatant for mass spectrometry analysis. Phosphoproteomic analysis of control and 
PTH samples was performed with the assistance of Dr. Michael L. Merchant
173
, 
University of Louisville, who enriched for phosphopeptides using sequential enrichment 
with TiO2 and IMAC resin, and identified proteins using high sensitivity, high mass 





Gene identification and pathway analysis: UniProt ID symbols were individually 
converted to gene names through Uniprot.org
174
. The functions of specific RNA-binding 
proteins identified within the phosphoproteome were also determined through 
Uniprot.org. Once gene names for all 1182 proteins were obtained, the gene list was 
submitted to DAVID for gene ontology analysis
175,176
. Opossum genes not recognized by 
DAVID software were converted to the orthologous human gene name (determined 
through Ensembl.org
177
) prior to DAVID analysis. Gene ontology for the dataset was 




Computational analysis of RNA-protein interaction prediction: The likelihood of RNA-
protein interaction was predicted using the RNA-Protein Interaction Prediction (RPISeq) 
software from the Dobbs and Honavar laboratories 
(http://pridb.gdcb.iastate.edu/RPISeq/)
178,179
, with opossum Npt2a 3’ UTR, KHSRP 
protein, and Roquin-2 protein sequences obtained from Ensembl.org. Random Forest 
(RF) or Support Vector Machine (SVM) classifiers were used to evaluate likelihood of 
interaction, with 0.5 and above considered the cutoff value for a positive prediction 
probability of RNA-protein interaction. 
 
Isolation of crude membrane, crude nucleus, and cytosol: Cells were treated as described, 
washed once with ice-cold PBS, and lysed in lysis buffer consisting of 5mM Tris 50mM 
Mannitol. Cells were lysed by passing the suspension through a 26G needle 15 times. 
Homogenate was spun at 1500*g for 5 min, and pellet was collected for crude nuclear 
fraction. Supernatant was transferred to a fresh tube and spun at 30,000*g for 45 min to 
pellet crude membranes (including the plasma membrane and endoplasmic reticulum), 
and the supernatant of spin two was collected as the cytosolic fraction. 
 
Sucrose density gradient centrifugation: Cells were grown to confluence in T-75 flasks 
and treated with low phosphate media or regular phosphate media for 24h. Cells were 
rinsed twice with ice-cold PBS and scraped in a buffer containing 5mM Tris-HCl, 50 mM 
mannitol, and phosphatase and protease inhibitors. Cells were homogenized with 10 
passes through a 26G needle, spun at 1500*g for 5 min, and pellet discarded. 1 mg of 
protein was loaded on top of a sucrose gradient made of stacked 200μL layers of 5 to 
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40% sucrose in Tris-Mannitol buffer. Gradients were centrifuged using a SW55 rotor at 
32,400 rpm for 16h. One 150 μL fraction was first collected from the top, followed by 
200 μL fractions for the rest of the gradient. Specific cell compartment fractions were 
determined by blotting each fraction for markers of the endoplasmic reticulum, plasma 
membrane, cytosol, and nucleus. Once the location of compartments was identified, 
fractions corresponding to a cell compartment were pooled, and 100 μL of each pooled 
fraction was combined with 33 μL Laemmli buffer and heated at 95°C for 5 min. 125 μL 
of each sample were loaded per lane onto a 10% polyacrylamide gel. 
 
Western blot analysis: Following protein estimation, equal amounts of membrane, 
nuclear, or cytosolic proteins were heated in Laemmli buffer at 95°C for 5 minutes to 
denature proteins. Protein samples were separated by SDS-PAGE and analyzed by 
Western blot, as previously described in Chapter IV. 
 
RNA-binding protein immunoprecipitation (RIP): RIP experiments were performed 
according to manufacturer’s protocol. Briefly, OK WT cells were grown to 95% 
confluence in T-75 flasks (Corning, Tewksbury, MA), and serum-starved overnight prior 
to treatment. Flasks were treated with 100nM PTH(1-34) or MEM (as control) for 2h. 
Afterwards, cells were rinsed twice with ice-cold PBS and scraped into 10 mL of PBS. 
Cells were collected by spinning at 1500 rpm for 5min at 4°C, and the supernatant was 
discarded. Cell pellets were resuspended in an equal pellet volume of RIP lysis buffer 
containing protease and RNase inhibitors. Lysates were incubated on ice for 5min and 
then stored overnight at -80°C. The following day, magnetic beads were prepared for 
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immunoprecipitation by incubating the beads with 5 μg antibody of interest or isotype 
IgG for 1.5h at room temperature, then washed three times. RIP lysates collected 
previously were quickly thawed and centrifuged at 14,000 rpm for 10min at 4°C. 100 μL 
of the supernatant was transferred to each antibody-beads complex. 10 μL of the 
supernatant was saved at -80°C as input for comparison of RT-PCR results. All of the 
tubes containing the antibody-beads complexes were incubated with rotation overnight at 
4°C. The next day, beads were washed 6 times with cold RIP wash buffer. Following the 
final wash, each immunoprecipitate was resuspended in 150 μL of Proteinase K Buffer 
consisting of 117 μL RIP wash buffer, 15 μL 10% SDS, and 18 μL proteinase K. All 
tubes were incubated at 55°C for 30min with shaking to digest the protein. Supernatants 
were collected and transferred to a new tube, and processed for RNA isolation. 
 
Isolation of RNA: RNA from digested RIP samples was isolated exactly as previously 
described in Chapter IV, from the addition of phenol:chloroform:isoamyl alcohol onward. 
 
Reverse transcription and real-time PCR: RT-qPCR was performed on RNA isolated 
from RIP experiments exactly as previously described in Chapter IV. PCR reactions were 
performed in triplicate, and the three data points averaged to obtain one Ct value per 
sample. IP efficiency was determined by comparing the fold difference (calculated as 




Immunohistochemistry: IHC was performed as described in Chapter IV. Antibodies 
against KHSRP and Roquin-2 were used at a dilution of 1:1000. Secondary biotin-
conjugated antibodies were also used at a dilution of 1:1000. 
 
Statistics:  Data are shown as mean ± SE.  The n values represent the number of 
independent experiments.  P values were calculated by Student’s t-test or by one- or two-
way ANOVA, followed by Bonferroni analysis using GraphPad Prism software.  A P 



















Part 1: The PTH-responsive phosphoproteome 
Through proteomic analysis, we identified 1183 individual proteins whose 
phosphorylation significantly changed in response to PTH. The gene names of 1139 
phospho-proteins were recognized by DAVID for functional analysis. DAVID mapped 
852 proteins out of the1139 submitted to one or more biological process categories. 
DAVID analysis identified 245 categories of biological processes regulated by PTH. As 
shown in Figure 19A, processes involved in transcription and its regulation were the top 
biological processes altered by PTH, followed by intracellular signaling and phosphate 
metabolism. 204 unique proteins, or 17.2% of the PTH-responsive phosphoproteome, 
were identified as effectors of transcription or regulators of transcription. Perhaps not 
surprisingly, protein localization (77 proteins) and amino acid phosphorylation (70 
proteins) are also major biological processes regulated by PTH. Processes governing cell 
cycle and macromolecular metabolism rounded out the top ten biological processes 
modified by PTH. 
DAVID also mapped 723 proteins to 96 categories of cellular location (Figure 
19B). The cellular compartment identified as having the most proteins (253) regulated by 
PTH is comprised of non-membrane-bounded organelles, which is defined as a structure 
of distinct morphology and function, but not bound by lipid bilayer. Types of structures 
included in this category are ribosomes, the cytoskeleton, and chromosomes. Other major 
cellular components regulated by PTH include the cytoskeleton (160 proteins), 





Figure 19: PTH-responsive phosphoproteome. Proteins identified as having undergone 
significant changes in their phosphorylation status in response to PTH were subjected to 
DAVID analysis. (A) Top 10 biological processes of the phosphoproteome. (B) Top 
cellular components of the phosphoproteome. 
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Of the 1139 phospho-proteins identified by DAVID gene ontology analysis of 
molecular functions, 68 proteins were categorized as having RNA-binding properties. 30 
of the phospho-RBPs underwent significant increases in their phosphorylation status 
within 30m of PTH treatment (Table 1, pages 101-102). 16 of the RBPs only exhibited 
increased phosphorylation after 2h of PTH treatment (Table 2, page 103), and the other 
22 RBPs underwent significant decreases in their phosphorylation status in response to 
PTH (Table 3, page 104). Within the category of fast-responding RBPs, PRPF31, a 
ubiquitously expressed pre-mRNA splicing factor
180
, underwent the largest increase in 
phosphorylation status. SRRM2, another splicing factor
174
, also had increased 
phosphorylation after 30m PTH, and was the most increased of all the RBPs at the 2h 
time point. 
Whereas most RBPs experienced increased phosphorylation within 30m of PTH 
treatment, some only responded after 2h of PTH stimulation. Of the delayed-responding 
RBPs, RPL7, a regulatory protein of the translation apparatus, experienced the biggest 
increase in phosphorylation. Also prominent in the delayed-responding RBP category 
was the cap-recognition protein eIF4A1, which also experienced a significant increase in 
phosphorylation after 2h of PTH treatment. 
The third category of RBPs consists of 22 RBPs that underwent a decrease in 
phosphorylation in response to PTH (negative-responding RBPs). Several underwent a 
transient dephosphorylation in response to 30m PTH, but regained their basal 
phosphorylation after 2h. Included in that category are ZC3HAV1, PDCD11, and 
SCAF1, proteins involved in viral mRNA degradation, ribosomal RNA biogenesis, and 
pre-mRNA splicing, respectively. NANOS3 experienced a transient dephosphorylation 
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with 30m PTH, but after 2h had phosphorylation levels 33 times greater than basal 
phosphorylation. EIF4G3, or eukaryotic translation initiation factor gamma 3, is a 
component of the protein complex that recruits ribosomes to mRNA, and in response to 
PTH, underwent a transient decrease in phosphorylation that increased above baseline 
following 2h PTH treatment. 
RNA-binding proteins serve several different functions, and only a subset of 
RBPS influence RNA stability. Preliminary functional analysis of the phospho-RBPs 
identified two RBPs that are known to modulate mRNA stability. The first, RC3H2, 
responded early to PTH treatment, with a significant increase in phosphorylation within 
30m of PTH that was sustained after 2h. RC3H2, more commonly referred to as Roquin-





through the use of Random Forest (RF) or Support Vector Machine (SVM) classifiers 
that Roquin-2 potentially interacts with the 3’UTR of Npt2a mRNA, with an SVM 
classifier value of 0.93. The second phospho-RBP of interest, KHSRP, only experienced 
an increase in phosphorylation after 2h of PTH. KHSRP is a multi-functional RBP, and 
one of its primary functions is to regulate mRNA stability
182,183
. RPISeq also predicted 
that KHSRP can interact with the 3’UTR of Npt2a mRNA, with an RF classifier of 0.85 
and an SVM classifier of 0.73. Predictive values above 0.5 are considered a positive 
indicator of protein-RNA interaction. As an initial analysis of the PTH-responsive RBPs, 
we chose to further explore the roles of KHSRP and Roquin-2 in the PTH response and 











Part 2: Regulation of KHSRP and Roquin-2 Expression by PTH 
 Computational analysis of the PTH-responsive phosphoproteome suggests that 
two of the PTH-responsive RBPs, KHSRP and Roquin-2, are capable of interacting with 
the 3’UTR of Npt2a mRNA. To confirm the expression of KHSRP and Roquin-2 in the 
proximal tubule, cell fractions prepared from OK cells treated with and without PTH 
were subjected to Western blot analysis. As shown in Figure 20A, KHSRP expression 
was found in crude membrane, nuclear, and cytosolic fractions. KHSRP nuclear 
expression was also found to significantly increase in response to PTH. IHC of control 
and PTH-D1 mouse kidneys also confirmed proximal tubular expression of KHSRP 
(Figure 20B), and showed a nuclear expression pattern as well as cytosolic and/or 
intracellular compartment expression with distinct prominence on the basolateral side of 
the cell. Increased nuclear expression of KHSRP was observed in the PTH-D1 kidneys in 
comparison to control, supporting the results of the OK cell Western blot study. 
 To strengthen the hypothesis that PTH-regulated KHSRP expression and activity 
is related to the control of phosphate transport by PTH, and not another PTH-regulated 
function, we next treated OK cells with low phosphate media, a stimulus for Npt2a 
upregulation. We reasoned that if KHSRP is involved in destabilization of Npt2a mRNA 
expression and its expression increased with PTH, then low phosphate should decrease its 
expression. Following 24h treatment with low phosphate media, cell compartments were 
isolated by sucrose density gradient centrifugation, and KHSRP expression analyzed by 
Western blot. We observed decreased expression of KHSRP in the plasma membrane and 
endoplasmic reticulum in response to 24h low phosphate, and increased KHSRP 







Figure 20: KHSRP expression in the  
proximal tubule. (A) Crude membrane, 
crude nucleus, and cytosol fractions were 
prepared from OK cells and Western blot 
analyses performed for KHSRP (top band, 
“K”) and β-actin (bottom band, “β”). Images 
shown are representative (n = 4). * is 
indicative of P < 0.05 versus control (0 h), as  
determined by one-way ANOVA. Percentages shown indicate relative changes of 
expression within each cell compartment. (B) Immunohistochemical staining for 
KHSRP in control FVB and PTH-D1 mouse kidneys.  (C) Plasma membrane (P.M.), 
endoplasmic reticulum (E.R.), nucleus, and cytosol fractions were prepared from OK 
cells treated with regular or low phosphate media, and blotted for KHSRP. 
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immunoreactive bands at different molecular weights than the typical 75kD band. 
Although we cannot conclusively comment on the functional importance of these 
potential variants, the presence of these bands with distinct cell compartment expression 
profiles indicates the possibility that KHSRP is expressed as several splice variants, with 
their functional role dependent on cellular distribution.  
In addition to examining the effect of PTH on KHSRP expression, we also studied 
the response of Roquin-2 to PTH treatment. As shown in Figure 21A, we identified 
Roquin-2 in the crude membrane, crude nucleus, and cytosolic fractions. PTH treatment 
over the course of 2h did not significantly affect crude membrane Roquin-2 expression. 
However, in both the nuclear and cytosolic fractions, Roquin-2 expression increased. 
When OK cells were treated with low phosphate media for 24h, Roquin-2 expression 
decreased in both the endoplasmic reticulum and nuclear fractions (Figure 21B). As with 
KHSRP, we found that the molecular weight of Roquin-2 differed between cell 
compartments, with a smaller immunoreactive band observed in the E.R. fraction as 
opposed to the Roquin-2 band in the nuclear fraction, again indicating the potential 
presence of compartment-specific splice variants. 
 
Part 3: Interaction of KHSRP and Roquin-2 with Npt2a mRNA 
 We have established that the expression of both KHSRP and Roquin-2 is 
responsive to PTH and ambient phosphate, physiological regulators of proximal tubular 
phosphate reabsorption. Computational analysis predicts that both proteins can interact 
with the 3’ UTR of Npt2a mRNA, but the expression studies alone do not provide 





Figure 21: Roquin-2 expression in the proximal tubule. (A) Crude membrane, crude 
nucleus, and cytosol fractions were prepared from OK cells and Western blot analyses 
performed for Roquin-2 (top band, “R”) and β-actin (bottom band, “β”). Images shown 
are representative (n = 4). * is indicative of P < 0.05 versus control (0 h), as determined 
by one-way ANOVA. Percentages shown indicate relative changes of expression within 
each cell compartment. (B) Plasma membrane (P.M.), endoplasmic reticulum (E.R.), 
nucleus, and cytosol fractions were prepared from OK cells treated with regular or low 
phosphate media. Fractions were separated by sucrose density gradient centrifugation, 
separated by SDS-PAGE, and Western blotted for Roquin-2.  
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mRNA. Therefore, to determine whether KHSRP and/or Roquin-2 interact with Npt2a 
mRNA, we next performed RNA-binding protein immunoprecipitation (RIP) assays, 
wherein an intact mRNP complex is pulled down with an antibody specific for an RBP, 
followed by RNA isolation and RT-qPCR to identify transcripts associated with the RBP. 
As shown in Figure 22A, immunoprecipitation of KHSRP pulled down Npt2a mRNA in 
comparison to isotype IgG IP. Immunoprecipitation of Roquin-2 also showed that Npt2a 
mRNA was pulled down with Roquin-2 (Figure 22B). While immunoprecipitation of 
KHSRP and Roquin-2 from PTH-treated cells showed less fold enrichment for Npt2a 
mRNA than in KHSRP and Roquin-2 IPs from control cells, normalization of Npt2a 
mRNA from the immunoprecipitation to Npt2a mRNA in the input will be necessary to 
determine whether more or less Npt2a mRNA is associated with the two RBPs in 















Figure 22: Interaction of KHSRP and Roquin-2 with Npt2a mRNA. IP of KHSRP or 
Roquin-2 followed by isolation of RNA and RT-qPCR was performed as described in 
Methods. Immunoprecipitation of (A) KHRSP (n=3) and (B) Roquin-2 (n =1) showed 




For the first time, we have characterized the cell-wide phosphorylation events that 
occur in response to PTH. We were able to categorize 1139 out of the 1182 proteins that 
underwent significant changes in phosphorylation over the course of 2h PTH treatment, 
and we discovered that PTH, along with being a major regulator of proximal tubule ion 
transport, is also a major regulator of both transcription and translation. Almost one-fifth 
of the downstream targets of PTH are proteins involved in the process of transcription or 
its regulation. This category of biological processes altered by PTH was by far the most 
affected biological process, distantly followed by the categories of intracellular signaling 
cascade (8.3%), phosphate metabolic process (6.9%), and protein localization (6.5%). As 
expected in characterizing the PTH-responsive phosphoproteome, we also found that 
PTH was also a major regulator of protein phosphorylation. 
We found that PTH was also a major regulator of translation, as we identified 68 
RNA-binding proteins whose phosphorylation status changed in response to PTH. 
Because DAVID was only able to map 812 of the submitted 1182 proteins to a molecular 
function, the number of RBPs regulated by PTH may be higher. Some of the RBPs 
modified by PTH-mediated signaling include members of the translation complex, such 
as EIF4G3, EIF2A, and EIF4A1. EIF4G3 is the linker protein between the 3’ and 5’ ends 
of mRNA, forming a closed-loop configuration that protects the mRNA from degradation 
by exonucleases
161
. PTH induces a transient dephosphorylation of EIF4G3, potentially 
affecting the stability of the closed-loop configuration and overall stability of the mRNP 
complex. 
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The destabilization of Npt2a mRNA in response to PTH is a specific event, and 
likely related to modified RBP interaction with the 3’UTR. The destabilizing effect of 
PTH on Npt2a mRNA is a rapid process, as PTH decreases the level of Npt2a mRNA 
expression by 50% from over 8 hours under basal conditions to just over 2 hours. We 
focused on exploring the roles of Roquin-2 and KHSRP in mediating this process, as both 
were predicted to interact with the Npt2a 3’UTR. 
KHSRP (hnRNPK-homology (KH)-type Splicing Regulatory Protein) is a multi-
functional RBP, and is involved not only in regulating mRNA stability, but also in 
mRNA localization and trafficking, pre-mRNA splicing, and miRNA maturation
184
. 
KHSRP mediates the rapid shortening of the poly(A) tail accompanied by 3’-5’ 
endonucleolytic decay by recruiting exosome machinery, including the enzymes poly(A) 
RNase (PARN), exosome component EXOSC2, and DCP2, the decapping 
enzyme
183,185,186
. KHSRP contains four KH domains, and all four domains are necessary 
for interaction with the decay-promoting exosome
187
. It is through these KH domains that 
KHSRP recognizes AREs in 3’UTRs of transcripts
184
. While the 3’UTR of Npt2a mRNA 
lacks the canonical AUUUA element, it nonetheless has type III AREs within U-rich 
regions, and two predicted binding sites for KHSRP. Both predicted binding sites for 
KHSRP within the 3’ UTR of Npt2a mRNA consist of the sequence GUCC, with one of 
the elements starting at base 7 (from the 3’ end) and the other starting at base 176
172
. The 
first binding site is situated very closely to the 3’ end of the mRNA (Figure 18C), which 
is predicted to be right next to the poly(A) tail of the mature transcript. This proximity in 
theory would facilitate the actions of recruited deadenylases to promote mRNA decay, 
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although it remains to be seen whether the 3’ binding motif is important for promoting 
destabilization. 
Much less is known about the function of Roquin-2 as an mRNA decay factor in 
comparison to the studies that have examined KHSRP-mediated RNA degradation. Loss 
of function mutations in Roquin are known to lead to a severe lupus-like autoimmune 
syndrome in mice
188,189
. Roquin-2 and its paralog Roquin-1 have redundant functions in 
T cells, and Roquin-2 can fully compensate for the loss of Roquin-1
189
. Because of this 
prominent systemic role of Roquin-2, the vast majority of Roquin-2 studies have focused 
on its effects on the immune system, and no studies to date have examined the role of 
Roquin-2 in the kidney. However, several studies have examined the mechanisms of 
RNA binding and promotion of decay by Roquin-2, and these mechanisms of mRNA 
regulation are likely to be conserved in other tissues. Roquin-2 recognizes and binds 
3’UTR cis-elements referred to as constitutive decay elements (CDEs), which are a 
conserved class of stem-loop motifs typically found in regulators of development and 
inflammation
181
. Upon binding, Roquin-2 induces mRNA decay by promoting a 
deadenylase complex
181
. Roquin-2 has two binding sites for RNA – one that recognizes 
stem-loop motifs, and another that recognizes double-stranded RNA – and both are 
required for promoting RNA decay
190
. We could not identify the conserved CDE stem-
loop motif in the opossum 3’ UTR of Npt2a, but we did find a CDE motif in the mouse 
3’UTR. While interaction with RNA requires a preserved CDE consensus in a stem-loop 
motif, recent studies suggest that Roquin-RNA binding is more dependent on secondary 
structures and non-sequence-specific contacts, implying that a broader spectrum of RNAs 




The studies within this chapter provide evidence that KHSRP and Roquin-2 are 
potential modulators of Npt2a mRNA stability. We showed that Npt2a mRNA was pulled 
down with both KHSRP and Roquin-2, which strongly suggests that both RBPs interact 
with the Npt2a transcript. Additionally, KHSRP and Roquin-2 expression is modulated 
by known regulators of Npt2a expression. Western blot showed a 10-fold increase in the 
nuclear expression of KHSRP after 2h PTH. This increase was also observed in the 
nuclei of PTH-D1 mouse proximal tubules in comparison to age-matched control mice, 
as determined through immunohistochemistry. While PTH treatment increased the 
nuclear expression of KHSRP, treatment of OK cells with low phosphate media, a 
stimulus for Npt2a upregulation, decreased both the plasma membrane and endoplasmic 
reticulum expression of KHSRP, and increased the cytosolic expression. Perhaps more 
interesting than the changes in expression are the differences in the molecular weight of 
KHSRP dependent on cellular location. Normally a 75 kDa protein, the predominant 
KHSRP band in both the plasma membrane and cytosolic compartments was around 40 
kDa. In the cytosolic fraction, low phosphate treatment stimulated an increase in KHSRP, 
and the appearance of a doublet in only the low-phosphate-treated condition suggests an 
increase in KHSRP phosphorylation. We also observed a shift in molecular weight in the 
plasma membrane compartment in response to low phosphate, from 40 kDa up to 75 kDa. 
These differences in the molecular weight of KHSRP likely indicate the expression of 
KHSRP splice variants, with potentially varying functions based on cell distribution. In 
the human genome, there are 10 known protein-coding splice variants of KHSRP
177,192
. 
However, further studies are required to properly interpret the functional significance of 
these changes in the OK cell. 
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The changes in Roquin-2 expression in response to PTH and low phosphate 
differed slightly from those of KHSRP. Whereas PTH induced only nuclear increases in 
KHSRP expression, Roquin-2 expression in response to 2h PTH increased in both the 
cytosolic and nuclear compartments by 342% and 207%, respectively. Separation of OK 
cell compartments by sucrose density gradient centrifugation following low phosphate 
treatment showed decreased expression of Roquin-2 in the E.R. and nucleus in response 
to 24h low phosphate. As observed with KHSRP, different molecular weights for 
Roquin-2 were found in the E.R. and nucleus. The typical band for Roquin-2 in the OK 
cell is approximately 55 kDa, which is the size found in the nucleus, but E.R. Roquin-2 is 
approximately 35 kDa. Again, these results may imply that Roquin-2 is expressed as 
several different splice variants, with differential functions of the Roquin-2 variants based 
on organelle location. Human Roquin-2 is known to be expressed as 7 different protein-
coding splice variants
177,192
, and it is likely that opossum Roquin-2 is expressed as several 
splice variants as well. 
 The studies regarding KHSRP and Roquin-2 expression in response to stimuli that 
regulate Npt2a expression are intriguing, and warrant further study to determine whether 
the interaction of those two RBPs with Npt2a mRNA serves to regulate Npt2a 
expression. Both KHSRP and Roquin-2 display an overall increase in expression in 
response to PTH and an overall decrease in expression in response to low phosphate. This 
inverse relationship to Npt2a expression indicates that KHSRP and Roquin-2 may act as 
destabilizing trans-factors for the Npt2a transcript. Interestingly, KHSRP modulates PTH 
mRNA decay rates in the parathyroid gland in response to changes in serum calcium or 
phosphate. This occurs through the interaction of KHSRP with type III AU-rich elements 
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in the PTH 3’UTR, which does not contain the classical AUUUA pentameric motif
164,182
. 
These are the same putative KHSRP-binding motifs found in the 3’UTR of Npt2a, and 
this relationship may indicate that KHSRP has a broader systemic role in the regulation 
of calcium and phosphate homeostasis. 
We have shown that KHSRP and Roquin-2 are responsive to PTH, with changes 
in both phosphorylation and expression. However, protein phosphorylation can either 
increase or decrease the activity of a protein, and we cannot make any conclusive 
statements about whether phosphorylation of Roquin-2 and KHSRP by PTH signaling 
upregulates or downregulates their decay-promoting function. Nothing is currently 
known about how post-translational modifications such as phosphorylation affect 
Roquin-2 activity. Several studies have, however, examined KHSRP activity in response 
to phosphorylation events. Known KHSRP phosphorylation events are induced by both 
the MAPK p38 and Akt/PKB pathways
193
. Phosphoproteomic analysis showed that PTH 
induces KHSRP phosphorylation at S181. S181 is within the K1 domain, one of the four 
KH domains required for binding RNA and recruiting exosomes. Although the functional 
significance of this particular modification is unknown, there are several studies that have 
addressed the effect of the phosphorylation of the neighboring S193 residue on KHSRP 
function. Akt mediates S193 phosphorylation, which promotes the unfolding of the K1 
domain, leading to decreased ARE binding and accumulation in the nucleus
193–195
. 
Although we have not addressed the change in KHSRP function induced by PTH, the 
phosphorylation of S181, which is also within the K1 domain, potentially has the same 
destabilizing effect on the domain structure as the phosphorylation of S193. Therefore, 
PTH may decrease KHSRP activity. While this action would typically stabilize KHSRP 
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target transcripts, several studies have shown that KHSRP can also mediate mRNA 
stabilization. Because we have not performed in vitro degradation assays of Npt2a 
mRNA in the presence and absence of KHSRP, we cannot currently make any conclusive 
statements about the role of KHSRP in regulating Npt2a mRNA stability. Further 
experiments are required to define the exact function of KHSRP and Roquin-2 in 




We conclude that PTH is a major regulator of transcription and translation in the 
proximal tubule. The RNA-binding proteins KHSRP and Roquin-2 interact with Npt2a 















DISCUSSION: BROADENED BASES AND FUTURE DIRECTIONS 
 
 The major impact of the work described within this dissertation lies in the 
establishment and description of an additional and alternative pathway for the regulation 
of Npt2a expression by PTH in the renal proximal tubule. As Npt2a expression is a major 
determinant of renal phosphate handling, total body phosphate homeostasis, and serum 
phosphate levels, the elucidation of newer mechanisms for the regulation of Npt2a by 
PTH holds promise for novel applications in clinical medicine. Because serum phosphate 
levels correlate with cardiovascular risk, understanding the determinants of serum 
phosphate may have important implications for the prevention and treatment of 
cardiovascular disease, the major cause of death in this country. 
 In Chapter IV, we discovered that PTH post-transcriptionally regulates Npt2a 
expression through destabilization of the Npt2a transcript, an effect that was dependent 
on both transcription and translation. In Chapter V, we observed that both the PTH-
induced PKA and PKC pathways contribute to PTH-mediated Npt2a mRNA 
destabilization. PKA activation appears to produce early changes in downstream effectors 
that provide sustained downregulation of Npt2a mRNA, and PKC activation produces 
later effects that promote mRNA decay after the initial period of PKA-induced 
destabilization. Chapter VI described the cell-wide phosphorylation events that occur in 
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response to PTH. We were able to identify two PTH-responsive RBPs, Roquin-2 and 
KHSRP, that bind to Npt2a mRNA and potentially regulate its stability in response to 
PTH.  
From these studies, we propose the following model of PTH-induced Npt2a 
destabilization (Figure 23): PTH stimulation of the PTH receptor activates both the PKA 
and PKC signaling pathways. PKA actions produce early and sustained downstream 
effects that lead to Npt2a mRNA destabilization, whereas PKC signaling contributes 
downstream signaling that acts during the latter phase of destabilization to sustain the 
phosphaturic effects of PTH. These signaling events lead to the increased expression and 
phosphorylation of Roquin-2 and KHSRP, which target Npt2a mRNA to expose the 
3’UTR and alter the stability of the basal Npt2a mRNP complex. Binding of KHSRP 
and/or Roquin-2 destabilizes the complex and promotes decay, potentially through 
exosome or decapping enzyme recruitment, followed by either deadenylation, 
exonucleolytic cleavage, endonucleolytic cleavage, or some combination thereof. Thus, 
we conclude that PTH post-transcriptionally regulates Npt2a expression through PKA- 
and PKC-dependent alteration of the stability of the Npt2a mRNP complex, promoting 
mRNA decay. 
Although we have provided evidence to support this conclusion, there are 
additional experiments that will be necessary to confirm our findings. While we have data 
that show that both Roquin-2 and KHSRP bind to Npt2a mRNA, and that both RBPs are 
responsive to physiological stimuli that regulate phosphate reabsorption, we have not 
conclusively shown that they mediate Npt2a mRNA decay in response to PTH. To 
determine their contribution to PTH-mediated Npt2a mRNA destabilization, knockdown 
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studies of Roquin-2 and KHSRP should be performed. If either or both RBPs are 
involved in regulating Npt2a mRNA decay in response to PTH, then silencing their  






Figure 23: Proposed model of PTH-mediated Npt2a mRNA destabilization. (1) 
PTH(1-34) binds the PTH receptor. (2) PTHR1 stimulation activates PKA, which 
produces early phosphaturic responses to PTH. (3) PKA activation is followed by PKC 
activation, which produces later effects to sustain PTH-induced phosphaturia. (4) 
Activation of second messenger signaling cascades alters the expression and 
phosphorylation status of the RBPs Roquin-2 and KHSRP. (5) Altered RBP composition 
of the Npt2a mRNP complex through differential binding/recruitment activities of 
Roquin-2 and/or KHSRP interrupts the closed-loop conformation, producing an unstable 
Npt2a mRNA complex, which leads to (6) exosome recruitment (potentially) and Npt2a 
mRNA decay. 
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 Also of interest in further exploring the contribution of Roquin-2 and KHSRP to 
the suppression of Npt2a expression are the changes in the cellular distribution of the two 
RBPs, and how those changes affect mRNA decay. We observed significant nuclear 
expression of KHSRP in response to PTH, and significant cytosolic and nuclear 
expression of Roquin-2. While some studies suggest that phosphorylation of KHSRP at 
different sites from the PTH-responsive serine residue promotes nuclear retention of the 
RBP and decreased mRNA destabilization, in neither OK cells nor mouse proximal 
tubules we did not observe a coordinate decrease in the cytosolic expression of KHSRP 
in response to PTH, suggesting that PTH-induced phosphorylation may produce different 
effects on KHSRP activity than has been previously reported. Roquin-2 expression, on 
the other hand, displayed a time-dependent increase in both the cytosol and the nucleus. 
Nothing is currently known about the effects of phosphorylation on Roquin-2 activity, 
and thus it would be beneficial to construct phosphorylation-deficient and -mimicking 
mutants of both KHSRP and Roquin-2 and examine how that alters the PTH responses 
regarding Npt2a mRNA in the proximal tubule.  
In addition to looking at the functional significance of Roquin-2 and KHSRP 
phosphorylation, future studies directed towards identifying the kinase responsible for 
their phosphorylation in response to PTH will further clarify the contribution of the PKA 
and PKC pathways to Npt2a mRNA decay. Our current studies suggest that the rapid and 
sustained stimulation of Roquin-2 phosphorylation may be in response to early PKA 
activity, whereas the later activation of KHSRP may be due to the prolonged signaling 
generated by PKC. Phosphoproteomic analysis identified residue S181 on KHSRP and 
residues T543 and S549 on Roquin-2 as being phosphorylated in response to PTH. Using 
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ScanSite to identify canonical kinase motifs within KHSRP and Roquin-2
196
, we found 
several kinases that were predicted to phosphorylate the particular residues responsive to 
PTH. Within Roquin-2, T543 is a canonical binding site for both Akt and 14-3-3 mode 1, 
whereas S549 is a putative phosphorylation site for GSK3 kinase, Erk1 kinase, and p38 
MAP kinase. Within KHSRP, S181 is predicted to be phosphorylated by calmodulin-
dependent kinase 2, CDK motif 1, and CDK motif 2. Although neither PKA nor PKC 
were predicted to directly modify the PTH-responsive sites on the RBPs, it is possible 
that PTH stimulates phosphorylation of other residues within the protein that were not 
detected by mass spectrometry, as both PKA and PKC were predicted to phosphorylate 
other residues within Roquin-2 and KHSRP. It is also possible that PTH stimulates the 
indirect activation of the aforementioned kinases through the activation of PKA and 
PKC. Further clarification would come from exploring the contribution of other PTH-
activated signaling pathways, both dependent and independent of PKA and PKC 
activation, to the overall effect on RBP activity and Npt2a mRNA stability.  
 As we identified KHSRP as a potential mediator of PTH-induced Npt2a mRNA 
degradation, it is interesting to note that KHSRP has been previously characterized as a 
regulator of PTH mRNA stability in the parathyroid gland. The further exploration of the 
role of KHSRP in regulating proximal tubular phosphate transport may allow for the 
discovery of common mechanisms for the regulation of mineral metabolism throughout 
multiple tissues in the body. While we chose to initially study the involvement of 
Roquin-2 and KHSRP in PTH-mediated Npt2a mRNA destabilization, other RBPs in the 
PTH-responsive phosphoproteome were also categorized by DAVID analysis as 
regulators of mRNA stability. These proteins include ZFP36L1, HNRNPD, and 
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HNRNPU. While HNRNPD and HNRNPU are ubiquitously expressed and not likely to 
be specific for PTH-induced Npt2a mRNA regulation, ZFP36L1 is another candidate 
protein that could possibly be involved in the regulation of Npt2a mRNA. Like KHSRP, 
the phosphorylation status of ZFP36L1 was increased after 2 hours of PTH stimulation, 
and it was also predicted by RPISeq to interact with the 3’ UTR of Npt2a mRNA. Thus, 
future experiments examining the potential role of ZFP36L1 in modulating Npt2a mRNA 
stability may yield promising results. Although we have already identified two PTH-
responsive RBPs that may regulate Npt2a mRNA stability, there are multiple RBP-
binding sites within the 3’UTR of Npt2a mRNA, and differential regulation of several 
RBP interactions, not just one, may be required for the full decay effect. 
 The fact that over 200 regulators and effectors of transcription are altered in 
response to PTH lends credence to our model of PTH-induced protein expression 
mediating Npt2a mRNA destabilization. While the decay response is rapid, PTH-
mediated downregulation of Npt2a mRNA and protein expression appears to reach a 
steady state. Chronic PTH stimulation greatly diminishes the apical expression of Npt2a, 
but it does not eliminate it entirely. Similarly, chronic PTH stimulation greatly diminishes 
Npt2a mRNA levels, but again, this effect reaches maximal suppression around 12h, 
achieving a new steady state of expression. We have identified the cellular responses that 
mediate the initial reduction in Npt2a mRNA, but further work remains to elucidate the 
chronic changes in the Npt2a mRNP complex that contribute to a rate of Npt2a mRNA 
decay equal to the rate of Npt2a mRNA synthesis.  
 We have answered several questions about the mechanisms behind the chronic 
downregulation of proximal tubular phosphate reabsorption by PTH, but we have also 
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generated many more. A century’s worth of research on the processes underlying the 
regulation of phosphate homeostasis has brought us to our current understanding, and yet 
the field of knowledge still remains incomplete. Within these chapters, however, we have 
expanded that knowledge base through the identification of a novel mechanism of Npt2a 
regulation by PTH, and we have provided a basis for continuing to explore the 
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-ATPase – sodium potassium ATPase 
NBC1 – sodium-bicarbonate cotransporter isoform 1 
NHE3 – sodium-hydrogen exchanger isoform 3 
NHERF-1 – sodium-hydrogen exchanger regulatory factor isoform 1 
Npt2a – type IIa sodium-phosphate cotransporter 
Npt2c – type IIc sodium-phosphate cotransporter 
PiT-2 – inorganic phosphate transporter isoform 2 
PTHR1 – PTH receptor type I 
RC3H2 – Roquin-2 




AC – adenylyl cyclase 
AKAP79/150 – A kinase anchor protein  
Akt – serine/threonine protein kinase; also referred to as Protein Kinase B 
cAMP – cyclic adenosine monophosphate 
Epac – exchange protein activated by cAMP 
ERK1/2 – extracellular-signal-regulated kinase 
FGF23 – fibroblast growth factor isoform 23 
GPCR – G-protein-coupled receptor 
IP3 – inositol triphosphoate 
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MAPK – mitogen-activated protein kinase 
PDE - phosphodiesterase 
PKA – protein kinase A 
PKC – protein kinase C 
PLC – phospholipase C 
PTH – parathyroid hormone 




RBP – RNA-binding protein 
CDE – constitutive decay element 
PDZ - post synaptic density protein (PSD95), Drosophila disc large tumor suppressor
 (Dlg1), and zonula occludens-1 protein (ZO-1) 
UTR – untranslated region 
mRNP – ribonucleoprotein complex composed of mRNA and associated RBPs 
PABP – poly(A) binding protein 
eIF4G - eukaryotic translation initiation factor 4 gamma 
eIF4E - eukaryotic translation initiation factor 4E 
ncRNA – non-coding RNA 
siRNA – small interfering RNA 
miRNA – micro RNA 
RISC - RNA-induced silencing complex 
ARE – AU-rich element 
ARE-BP – AU-rich element binding protein 
HuR – Human antigen R 
ELAVL1 - embryonic lethal abnormal vision-like 1; synonym for HuR 
RIP – RNA-binding protein immunoprecipitation 
IP - immunoprecipitation 
eIF4A1 - eukaryotic translation initiation factor 4A1 
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8-Br-cAMP – 8-bromo-cyclic adenosine monophosphate 
Act D – actinomycin D 
ANOVA – analysis of variance 
BBM – brush-border membrane 
BLM – basolateral membrane 
BSA – bovine serum albumin 
Chx - cycloheximide 
CM – crude membrane 
CPM – counts per minute 
CPZ - chlorpromazine 
DAB - 3,3'-Diaminobenzidine 
DAG - diacylglycerol 
DAVID - The Database for Annotation, Visualization and Integrated Discovery 
FVB – background strain of transgenic PTH-D1 mice 
H-89 – pharmacologic inhibitor of PKA 
HRP – horse radish peroxidase 
IHC - immunohistochemistry 
OK – opossum kidney 
PKCi – PKC inhibitor peptide 
PMA – phorbol myristate acetate 
PTH-D1 – transgenic mouse strain featuring parathyroid-specific cyclin D1
 overexpression 
RF – Random Forest 
RPISeq - RNA-Protein Interaction Prediction 
RT-qPCR – reverse transcription quantitative polymerase chain reaction 
SDS-PAGE - sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SVM – Support vector machine 
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